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Fat in hearts: Uptake, storage, and turnover 
Chad M Trent 
Abstract 
The heart is one of the most energy demanding organs and is metabolically flexible to meet those 
demands. A major fraction of the hearts energy is derived from the uptake of circulating lipids; 
this dissertation reviews general pathways of lipid metabolism and then discusses how the heart 
obtains lipids and how these lipids are processed once inside the heart. Furthermore, 
derangements in lipid uptake and processing that are associated or causative of cardiac 
dysfunction are discussed. A new finding describes how the mouse heart requires lipoprotein 
lipase derived fatty acids for intracellular lipid droplets formation. Finally, the implications of 
these findings and future studies are described.  
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Chapter 1: Introduction to lipid metabolism 
Overview of lipids 
Lipids are a class of organic molecules that are defined as soluble in organic solvents and 
weakly soluble in water. These molecules can organize in large, supramolecular structures 
through noncovalent interactions to form membranes and droplets. Lipids perform three major 
roles in living cells. First, lipids are a major component of membranes, facilitating 
compartmentalization and separation. Lipids containing hydrocarbon chains can function as an 
efficient long-term energy storage form. Finally, lipids are important molecules for cellular 
signal transduction.  
One of the major lipid classes is the fatty acid (FA). FAs are weak acids that are usually 
comprised of an even number of carbon atoms with one carboxyl group. Due to this carboxyl 
group, FAs are sequestered into lipids that are more complex by their sequential esterification 
(1). The major energy storage molecule for eukaryotic organisms is triglyceride (TG), which is 
comprised of three FAs esterified to a glycerol backbone. In general, non-esterified FA (or free 
fatty acid, FFA) concentrations are kept at very low concentrations inside of cells by near 
constant incorporation into TGs or via stepwise oxidation to produce energy. Since FAs contain 
high numbers of single bonds, they are particularly suited to stepwise oxidation to produce an 
enormous amount of reducing equivalents for mitochondrial oxidative production of adenosine 
triphosphate (ATP), the energy currency of the cell. 
Phospholipids and sphingolipids are formed from the esterification of FAs to other 
organic compounds. Phospholipids are comprised of two FAs esterified to glycerol, typically in 
the sn-1 and sn-2 positions, and a phosphate group esterified to the sn-3 position (1). There are a 
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number of hydrophobic head groups, including but not limited to choline, serine, and 
ethanolamine, which are esterified to the phosphate group. Phospholipids are amphipathic 
molecules and are the major lipid constituent of cell membranes. Furthermore, membrane 
phospholipids are hydrolyzed to release FAs, diacylglyceride (DAG), or their head group; these 
molecules can activate intracellular signaling pathways. Sphingolipids are similar molecules, 
comprised of except that they are consist of a FA amide-bonded to a serine (1). Ceramides are 
formed from the addition of an additional FA in an amide bond to a sphingolipid. These 
molecules are major cell membrane lipids and function as signaling molecules. 
Another class of lipid molecules are the sterols, which are important as cell membrane 
constituents, for formation of bile salts, and in the generation of steroid hormones. Free 
cholesterol is esterified with a FA to form a cholesteryl ester; this is the major storage and 
circulating form of cholesterol.  
Activation of lipids 
After FFA enters a cell, it is thioesterified to a CoASH molecule by a class of enzymes 
called long-chain acyl-CoA synthetases (Acsl). The fatty acyl-CoA molecule can enter a number 
of pathways, including mitochondrial β-oxidation or esterification into TGs (2). There are 5 
canonical Acsl enzymes, as well as 6 FA transport proteins that have Acsl activity, postulated to 
have differing roles in directing FAs to distinct cellular fates. The best characterized of these is 
ACSL1, which is responsible for synthesis of acyl-CoA at the cell membrane and directing FFA 
to β-oxidation (3,4). 
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Esterification of lipids 
Due to the relatively nonpolar hydrocarbon chain in FAs, lipids droplets are the most 
entropically stable form in an aqueous environment. Therefore, the majority of TGs in cells exist 
as lipid droplets. These droplets cannot easily traverse cell membranes and must be partially 
degraded to release FFAs that can enter or exit a cell. Almost all cell types possess the ability to 
esterify acyl-CoA into TG (5). The two tissues with the most TG esterification are the liver and 
the white adipose tissue (WAT). In the liver, glycerol kinase can phosphorylate free glycerol, 
which forms the backbone for sequential esterification of two fatty acyl-CoA substrates in the sn-
1 and sn-2 positions via the action of glycerol-3-phosphate acyltransferase and then acyl-glycerol 
phosphate acyltransferase to produce phosphatidic acid. Phosphatidic acid is converted to DAG 
via dephosphorylation of the phosphate group esterified to the sn-3 carbon by phosphatidic acid 
phosphatase. This process is much the same in white adipose tissue, except that glycerol-3-
phosphate is produced from the NADH-dependent reduction of the glycolytic intermediate 
dihydroxyacetone phosphate. 
Once DAG is synthesized, the final (and rate-limiting) step of TG synthesis is catalyzed 
by the enzyme diacylglycerol acyltransferase (DGAT). This enzyme esterifies a fatty acyl-CoA 
on the sn-3 position of diacylglycerol. There are two known DGAT isoforms – Dgat1 and Dgat2 
– that are expressed in most tissues (5). Dgat1 was the first gene to be cloned and then knocked 
out (6,7); these knockout mice were resistant to weight gain and had reduced adipose tissue 
mass, but DGAT activity was still detected in some tissues. Shortly thereafter, a second Dgat 
was identified in a fungal species and then detected via sequence homology in mammalian 
tissues (8). When Dgat2 was knocked out in mice, these mice died shortly after birth due to skin 
barrier defects because of inability to synthesize TGs in the skin (9). These studies (and others) 
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illustrate both the redundant roles of DGAT1 and DGAT2, as well as distinct roles for each 
enzyme (10). Interestingly, Dgat1 also catalyzes a number of other reactions – it has the ability 
to make retinyl esters from retinol and acyl-CoAs (11). 
Fatty acid oxidation 
FAs are the most energy-rich substrates for ATP production in cells. As mentioned, FAs 
are activated by ACSLs to acyl-CoA molecules that can then enter multiple pathways. Short and 
medium chain acyl-CoA molecules can enter directly into the mitochondrial matrix for β-
oxidation, but long chain (more than 10 carbons) must undergo a multi-step process to enter the 
mitochondrial matrix (12). The first, and rate-limiting, step is the exchange of the CoA cofactor 
for a carnitine molecule, by the enzyme carnitine-palmitoyltransferase 1 (CPT1). There are 
multiple CPT1 isozymes; CPT1A is liver specific, CPT1B is primarily expressed in heart and 
skeletal muscle, and CTP1C is expressed in the brain (13). The critical importance of these 
enzymes are emphasized by the phenotype of human loss-of-function mutations; impaired 
energy production from fat means these patients are prone to hypoglycemia and fatigue, but diets 
enriched in short- and medium chain FAs can ameliorate the deficiency (13).  
Acylcarnitines enter the mitochondrial matrix via the carnitine-acylcarnitine translocase, 
where a second enzyme, CPT2, re-exchanges the carnitine for another CoA (13). The 
regeneration of the acyl-CoA inside the mitochondrial matrix is thus able to begin β-oxidation. In 
brief, acyl-CoA is oxidized by acyl-CoA dehydrogenases that catalyze the stepwise removal of 
acetyl-CoA and production of NADH and FADH2 (14). These reducing equivalents enter the 
electron transport chain to drive oxidative phosphorylation, and the acetyl-CoA enters the 
tricarboxylic acid cycle to generate more reducing equivalents. 
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Figure 1 - Uptake, storage, and oxidation of fatty acids 
 
FFAs may enter a cell through a number of transporters or via flip-flop. Inside of the cell, FFAs 
are activated by the thioesterase ACSL, at which point they are directed to mitochondrial β-
oxidation or sequential esterification. CPT1 directs fatty acyl-CoAs to β-oxidation, whereas 
monoacylglycerol acyltransferase (MGAT) and DGAT direct fatty acyl-CoAs towards 




Fatty acid synthesis 
Just as FAs are oxidized to yield reducing equivalents and acetyl-CoA, the reverse 
process can also occur. Acetyl-CoA and malonyl-CoA can be ligated and reduced to form long-
chain FAs via a multistep process (15). First, acetyl-CoA carboxylase (ACC) adds a CO2 to the 
acetyl-CoA to yield malonyl-CoA. This molecule is the substrate for FA synthase (FASN); 
through a series of NADPH-dependent reductions, two carbons derived from acetyl-CoA are 
added and the CO2 is removed, leading to an extension of two carbons at every step (16).  FASN 
is a homodimeric protein that has two acyl carrier protein regions; at one site, the nascent FA is 
bound, and the other site binds the additional malonyl-CoA that added to the growing FA (17). 
The other regions of FASN are responsible for enzymatic reductions and dehydrations that 
catalyze formation of the FA. Malonyl-CoA is also a potent allosteric inhibitor of CPT1, and it is 
thought that tissues that have low de novo lipogenesis use a second enzyme, ACC2, to produce 
malonyl-CoA in order to decrease the rate of β-oxidation (18). The major product of de novo 
lipogenesis is palmitate (C16); longer FAs may be produced by the elongation-of-very-long-
chain-FAs (ELOVL) enzymes (19). Unsaturated and polyunsaturated FAs can be formed by a 
class of enzymes called the stearoyl-CoA desaturases (SCDs) (19). 
Dietary lipid absorption and circulation 
Dietary lipids primarily exist as TGs. The major site of dietary lipid absorption is in the 
small intestine. TGs are first emulsified in combination with bile salts secreted from the gall 
bladder and then degraded, primarily by pancreatic lipase, to form FFAs and monoglycerides 
(20). These lipids form a mixed micelle, which adsorbs onto the surface of the enterocytes and 
then are taken up into the enterocyte – long and very-long chain FAs are transported primarily 
via the FA transporter cluster of differentiation 36 (CD36) (21). These FFAs and monoglycerides 
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are repackaged in a stepwise process to enter circulation. First, the FFAs and monoglycerides are 
re-esterified into TGs, primarily via the two enzymes diacylglycerol acyltransferase (DGAT) 1 
and 2 that catalyze the final step in TG synthesis (10). Monoglycerides and FFAs are esterified to 
form DAG by the enzyme monoacylgycerol acyltransferase (MGAT) (22). Cholesterol, as well 
as retinol (vitamin A), are similarly hydrolyzed, absorbed, and re-esterified with FAs (23). These 
TGs are loaded into a nascent lipoprotein via the protein microsomal TG transfer protein 
(MTTP). Apolipoprotein B48 (ApoB48), a truncated splice-isoform of the full ApoB mRNA 
transcript, is the constituent apolipoprotein. These newly formed particles are termed 
chylomicrons (CM) and transport dietary lipids from the enterocyte into the lymph. Via the 
lymphatic circulation, CMs are transported into the vena cava to the heart and then pumped 
throughout the body. 
Once the CMs enter the blood circulation, many tissues use them as a source of energy. 
The major destinations for chylomicron lipids are the heart, skeletal muscle, and adipose tissue; 
however, other organs also take up some CM lipids. Approximately 50% of chylomicron TGs 
along with most of the ApoB48, retinyl esters, and cholesteryl esters are cleared from the 
circulation by the liver (24). The TG core of the chylomicron must be hydrolyzed into FFAs so 
that these FFAs can enter cells. Lipoprotein lipase (LpL) is the major enzyme responsible for the 
hydrolysis of circulating TGs; however, there are other identified lipases in the vascular 
endothelium such as hepatic lipase and endothelial lipase, but their substrates are not large TG-
rich lipoproteins (25). LpL is secreted as a catalytically active dimer, primarily from muscle cells 
and adipocytes, and is bound to the endothelial cell surface via the glycosylphosphatidylinositol 
anchored high-density lipoprotein binding protein 1 (GPI-HBP1) anchored in the vascular 
endothelium and heparan-sulfate proteoglycans (26,27). Once FAs are liberated from the core 
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TG of chylomicrons, they can enter cells and be oxidized for ATP production or re-esterified and 
stored as TG. The liver can take up the TG-depleted CMs via receptor-mediated endocytosis; this 
is the major pathway for delivery of dietary cholesterol and fat-soluble vitamins to the liver (24). 
LpL activity is regulated at multiple levels. At the most basic level, high FFA 
concentrations inhibit LpL activity through product inhibition in both in vivo and in vitro 
experiments (28-30). LpL activity is increased by the binding of the apolipoprotein C (ApoC)II, 
and inhibited by the binding of ApoCI and ApoCIII (25). Transgenic mice that overexpress 
human ApoCI or ApoCIII have hyperchylomicronemia due to attenuated LpL activity (31,32). 
Although ApoCII deficiency also caused hypertriglyceridemia (33), overexpression of ApoCII 
also inhibited LpL activity by interfering with CM binding to heparin sulfate proteoglycans (34). 
Fasting decreases white adipose tissue LpL activity via the local secretion of angiopoietin like 4 
(AngPtl4), which inhibits LPL lipoprotein lipase by breaking apart the catalytic dimer (35). LpL 
transcription and translation are positively regulated by insulin stimulation in adipose tissue 
(36,37); transcriptional regulation of LpL is discussed later. 
Alternate pathways for TG uptake also exist; however, these seem to mostly function 
either in concert with or complementary to the activity of LpL. Two additional extracellular TG 
lipases, hepatic lipase and endothelial lipase, belong to the same gene family as LpL (38,39). 
Hepatic lipase is secreted from hepatocytes and binds to the vascular epithelial cells of the liver; 
similar to LpL, it plays a role in both hydrolyzing circulating TG as well as anchoring 
lipoproteins and increasing endocytosis via the LDL receptor (40). This anchoring activity is 
most important for the uptake of CM remnants in the liver (41). Endothelial lipase is synthesized 
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and secreted from endothelial cells; although it has some TG lipase activity, there is much higher 
activity for the hydrolysis of lipoprotein phospholipids (39).  
The VLDL receptor can facilitate TG uptake via endocytosis of -rich lipoproteins; in 
particular, it recognizes ApoE containing particles – excluding uptake of LDL (42). VLDLR is 
expressed in non-hepatic tissue and is most abundant in the brain. VLDLR deficient mice have 
normal circulating TG concentrations (43); later studies suggest VLDLR may be most important 
for anchoring circulating TG-rich lipoproteins and increasing LpL activity (42,44,45).  
In vivo models of lipoprotein lipase function 
Since the advent of knockout and transgenic mouse models, there have been a number of 
knockout and transgenic mice that have characterized LpL in vivo. The first LpL knockout 
mouse was described in 1995 by Levak-Frank et al. (46) and exhibited severe 
hypertriglyceridemia and died shortly after birth. Concurrently, a transgenic mouse that had 
muscle-specific overexpression of human LpL (MCK-LpL) was developed (46). The MCK-LpL 
mouse exhibited dramatically lower plasma TG and extensive mitochondrial proliferation in 
skeletal muscle, and this transgene was able to rescue the post-natal lethality in the LpL 
knockout mice.  
Later, LpL was floxed and a cardiac specific knockout of LpL (hLpL0) was developed 
(47). This mouse had reduced heart LpL activity and increased plasma TG. Furthermore, these 
mice exhibited increased heart glucose and FFA uptake, but a decreased expression of PPARα 
target genes involved in FA oxidation. These hLpL0 mice were further characterized to have 
increased glucose oxidation and decreased FA oxidation, and eventually developed cardiac 
dysfunction (47). Similar results were observed using an inducible, cardiac-specific knockout of 
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LpL (48). These studies implicate the critical role of circulating TG in providing energy 
substrates for the heart, and is discussed in more detail in Chapters 2 and 3. 
More recently, LpL has been knocked out in several other tissues. Skeletal muscle-
specific LpL deletion led to increased muscle glucose uptake and increased insulin sensitivity, at 
the expense of decreased glucose uptake and insulin resistance in other tissues (49). LpL was 
thought to be a major factor in adipose tissue accretion of TG mass; surprisingly, despite 70-85% 
reductions in LpL activity the white-adipocyte specific LpL knockout mouse has relatively 
normal WAT mass, but decreased brown adipose tissue (BAT) size and function (50). Mass 
spectrometry analysis indicated an altered WAT FA profile with less abundance of dietary lipids 
(linoleic acid), probably being compensated for by de novo lipogenesis; this is similar to 
observations in the adipose tissue of LpL-deficient humans (51).  
Neuron-specific LpL knockout mice become obese on chow diets at 4 months of age, 
which was attributed to increased food intake and decreased energy expenditure (52). TG uptake 
in the hypothalamus was significantly reduced, which suggests that circulating lipids play a role 
in modulating central regulation of metabolism. Finally, macrophage-specific deletion of LpL 
had less severe development of atherosclerotic lesions, indicating a role for LpL in development 
of atherosclerosis (53). Interestingly, there was no difference in adipose tissue mass or adipocyte 
size in these mice, despite the abundance of adipose tissue macrophages. It is unclear exactly 
why there was less atherosclerosis in these mice; however, it was suggested that a secondary 
decrease in FA transporter CD36 expression or impaired macrophage energy availability might 
decrease macrophage infiltration.  
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Similar to models of LpL deficiency, the GPI-HBP1 knockout mouse closely resembles 
the phenotype of the LpL-knockout mouse model (27). These mice have hyperchylomicronemia 
and impaired postprandial clearance of lipids; it was suggested that GPI-HBP1 is important for 
anchoring of chylomicrons. It was later demonstrated that this protein helps LpL to migrate from 
its origin in myocytes or adipocytes to the capillary endothelium (26).  
Characterization of the fatty acid transporter cluster of differentiation 36 
After the lipolysis of circulating TG and release of FFA, these FFA are taken up into 
tissues. Although at least some FFA can pass directly through the membrane via flip-flop and 
diffusion (54), a majority of FFA uptake is facilitated by transport proteins. The most essential 
and best-characterized FFA transporter is the scavenger receptor cluster of differentiation 36 
(CD36) (55). Generation and study of Cd36-/- mice elucidated the primary roles of CD36 as a 
fatty acid transporter for the adipocyte, as well as confirmed earlier evidence that CD36 mediates 
macrophage uptake of oxidized LDL particles (56). Cd36-/- mice had elevated plasma FFA and 
TG, as well as a decrease in circulating glucose. This decrease in circulating glucose is probably 
due to a metabolic compensation due to decreased availability of lipid substrates for energy 
production, as these mice were later shown to be more insulin and glucose sensitive when fed a 
high-glucose diet (57).  
Later studies demonstrated the critical role of CD36 in uptake of FFA into heart and 
skeletal muscle; uptake of a synthetic FFA analog (15-(p-iodophenyl)-3-(R, S)-methyl 
pentadecanoic acid) was reduced about 50% (58). Notably, Cd36 deletion did not impair FFA 
uptake into the liver, suggesting that other FA transporters may be more important. However, 
chronic high-fat diet feeding increased CD36 in the liver, and adenoviral hepatic overexpression 
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of Cd36 exacerbated fatty liver. Furthermore, Cd36-/- mice were protected from high-
carbohydrate and alcohol diet feeding induced hepatic steatosis (59). Diet-induced obese mice 
had increased liver CD36 protein expression, and adenoviral-mediated liver Cd36 
overexpression further increased liver FFA uptake and TG content, suggesting that CD36 will 
transport FFA into hepatocytes during states of caloric excess (60). These data suggest that 
CD36 is an important pathologic liver FA transporter in the context of chronic caloric excess and 
hepatic dysfunction. 
A number of studies have elucidated the intimate relationship between LpL and Cd36 in 
the absorption of circulating TGs – both chylomicron and VLDL TG. Cd36 deficient humans 
have increased postprandial hypertriglyceridemia (61); knockout mice have a similar phenotype 
attributed to decreased LpL activity secondary to Cd36 deficiency (29). An in vitro LpL activity 
assay incubated with plasma from Cd36-/- mice demonstrated that product inhibition was 
probably responsible for the decreased LpL activity in vivo. It was later demonstrated that, when 
crossed onto a heart specific LpL knockout, the heart had decreased uptake of VLDL TG, but not 
CM TGs (30). These data suggest that CD36-mediated FFA uptake is saturable and very high 




Additional proteins involved in FFA transport 




CD36 Fatty acid translocase (FAT) 
FATP1 
Solute carrier family 27, member 1 (SLC27A1), Acyl-CoA synthetase very long chain family 
member 4 (ASCVL4) 
FATP2 
Solute carrier family 27, member 2 (SLC27A2), Acyl-CoA synthetase very long chain family 
member 1 (ASCVL1) 
FATP3 
Solute carrier family 27, member 3 (SLC27A3), Acyl-CoA synthetase very long chain family 
member 3 (ASCVL3) 
FATP4 
Solute carrier family 27, member 4 (SLC27A4), Acyl-CoA synthetase very long chain family 
member 5 (ASCVL5) 
FATP5 
Solute carrier family 27, member 5 (SLC27A5), Acyl-CoA synthetase very long chain family 
member 6 (ASCVL6) 
FATP6 
Solute carrier family 27, member 6 (SLC27A6), Acyl-CoA synthetase very long chain family 
member 6 (ASCVL2) 
FABP1 Liver fatty acid-binding protein (LFABP) 
FABP2 Intestinal fatty acid-binding protein (IFABP) 
FABP3 Muscle and heart fatty acid binding protein 
FABP4 Adipocyte fatty acid-binding protein (AFABP), Adipocyte protein 2 (AP2) 
FABP5 Epidermal fatty acid-binding protein (EFABP) 
FABP6 Ileal fatty acid-binding protein (ILBP) 
FABP7 Brain fatty acid-binding protein (FABPB) 
GOT2 Fatty acid binding protein, plasma membrane (FABPpm) 
 
Other than CD36, there are additional proteins that facilitate uptake of circulating FFA 
(Table 1). The FA transport protein (Fatp) proteins belong to a gene family that can complement 
or replace CD36 in certain tissues. Fatp1 was first identified in a library screening strategy and 
proposed as a FA transporter (62); expression profiling revealed the highest expression in muscle 
and adipose tissue (63). It was later shown that FATP1-mediated FA transport was insulin 
sensitive, and that insulin stimulation promoted the translocation of FATP1 from intracellular 
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membranes to the cell surface (64). This effect was abolished in FATP1 knockout mice (65). 
FATP1 has both FA transport abilities as well as ACSL activity; cell culture studies indicate a 
particular role for directing FAs to TG synthesis (66). Fatp1 deficient mice were protected from 
diet-induced obesity induced skeletal muscle insulin resistance, which suggests a causative role 
for lipid uptake in skeletal muscle in the development of insulin resistance (65). However, it is 
also likely that skeletal muscle that has defective FFA uptake may compensate by increasing 
uptake of glucose. Fatp1 is also essential for BAT thermogenesis; it was suggested that this was 
a result of decreased FFA uptake in BAT, but it could also be due to decreased ACSL activity 
(67). 
Five additional Fatp family member, Fatp2 through Fatp6, were later identified using 
genomic sequence analysis based on sequence homology (68). Fatp2 was identified as being 
primarily expressed in the liver and localized to the peroxisome; although this enzyme was 
particularly important for peroxisomal transport of very long (greater than C22) chain FA, as 
well as having ACSL activity, knockout mice that had reduced peroxisomal β-oxidation did not 
have any accumulation of VLCFAs (69). Later studies indicated the FATP2 is primarily 
localized to the plasma membrane and critical for liver uptake of LCFAs – knockout mice had 
40% reduced liver FFA uptake and 50% reduced peroxisomal oxidation (70). 
Fatp3 is primarily expressed in testis, ovary, and adrenal glands and exhibits both FA 
transport activity as well as ACSL activity (71); it is primarily localized to the mitochondria. 
RNA interference experiments in cultured cells implicated FATP3 primarily as an ACSL enzyme 
rather than a FA transporter. Fatp4 was identified as being a major intestinal FA transporter (72); 
however later investigation suggested that the FATP4 was primarily an ACSL enzyme; 
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overexpression of a mitochondrial-specific ACSL was also able to increase FA uptake (73). 
Human genetics studies implicated defective FATP4 activity in development of ichthyosis due to 
the reduced ability to esterify VLCFA into phospholipids, cholesteryl esters, and TGs (74). 
Fatp3 and Fatp4 may be particularly important for transcellular FFA uptake, as a very high level 
of mRNA expression of both genes was found in endothelial cells of the heart, skeletal muscle, 
and BAT (75). 
The fifth family member Fatp5 is most abundantly expressed in the liver. FATP5 exhibits 
ACSL activity for VLCFAs (C18, C20, C24, C26) (76), and also has thioesterification activity 
for cholate, suggesting that it may play a role in hepatic bile synthesis (77). Fatp5-/- mice were 
generated and demonstrated lower FFA uptake in isolated hepatocytes, as well as lower liver TG 
and FFA concentrations (78). In concordance with the importance for bile acid production, 
Fatp5-/- mice have altered bile acid composition due to decreased choline conjugation to taurine 
and glycine (79). Since CD36 seems to have a negligible role in physiologic liver FFA uptake 
(58,80) – and actually have increased hepatic TG deposition (81) —, it is likely that FATP2 and 
FATP5 are the primary physiologic FFA transporters in the liver.  
Finally, Fatp6 is most abundantly expressed in the heart and is localized to the 
cardiomyocyte sarcolemmal membrane, colocalizing with CD36 (82). In vitro experiments 
demonstrated that Fatp6 could transport FFA. Sequence analysis suggests that Fatp6 also has 
ACSL activity, but there is no direct evidence (83). There have been no reports of Fatp6 




Another class of proteins involved in FFA transport are the intracellular FA binding 
proteins (FABPs). These proteins bind hydrophobic molecules inside of cells, such as FFA and 
acyl-CoA. The first FABP to be cloned was most highly expressed in the liver, and was initially 
called the liver FABP (FABP1) (84). Crystallization reveals that FABP1 forms a β-barrel 
structure with a hydrophobic core that can reversibly bind palmitate (85). Cell culture studies as 
well as human loss-of-function mutants implicate FABP1 in modulating the uptake of circulating 
lipids (86,87). Fabp1-/- mice were somewhat protected from diet-induced obesity and nearly 
completely protected from hepatic lipid accumulation, but increased systemic glucose catabolism 
(88). Forty-eight hour fasted Fabp1-/- mice had much lower hepatic FFA uptake, but relatively 
normal fasting-induced gene expression (89). FABP1 can localize to cell nuclei as well as bind to 
the transcription factors PPARα and PPARγ, suggesting that it may play a role in ligand binding 
to hormone receptors (90). Taken together, these studies strongly implicate FABP1 as an 
intracellular protein that sense hepatic lipid contents to modulate uptake.  
Sequence analysis of the Fabp1 cDNA was used to discover homologous mRNAs and to 
identify an intestinal FABP (FABP2) (91). Human genetics studies implicated gain-of-function 
mutations in FABP2 as a predictor for increased plasma TG as well as cardiovascular and 
metabolic diseases (92,93). Intestinal FABP was thought to facilitate dietary lipid absorption and 
CM-TG secretion. Female Fabp2-/- mice weighed less on both chow and high-fat diet feeding, 
whereas chow-fed male Fabp2-/- mice weighed more and were only slightly protected from diet-
induced obesity (94). It is unclear why this occurred, but FABP1 and FABP2 probably have 
distinct roles in transport of their ligands towards oxidation versus storage (95). It is clear that 
FABP2 is not essential for dietary lipid absorption; this mainly demonstrates the multiple 
redundancies in pathways of lipid absorption. 
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Fabp3 is most highly expressed in the heart, particularly after birth reflecting the 
increased reliance on the postnatal heart on lipid metabolism (96). Fabp3 is also expressed in 
mammary tissue, but Fabp3-/- mice have no overt mammary phenotype (97). The most striking 
phenotype of Fabp3-/- mice was a 90% reduction of cardiac FA uptake and decreased FA 
oxidation, compensated for by increased glucose uptake and oxidation. These mice later 
developed cardiomyopathy (98,99). FABP3 is also expressed in the skeletal muscle, but 
knockout mice had a minimal reduction in muscle FFA uptake (100). Interestingly, brain lipids 
were also reduced – with long chain FFAs and total phospholipids reduced around 20% (101).  
The fourth family member was initially characterized as adipocyte protein 2 (aP2, now 
known as Fabp4) due to high expression in white adipocytes and macrophages (102,103). 
Interestingly, Fabp4-/- mice gained more weight than wild-type mice on a high fat diet, but were 
protected from insulin resistance and adipose tissue inflammation (104). FABP4 overexpression 
in macrophages alleviated lipid induced ER stress (103). Human genetic studies also implicates 
loss-of-function mutations in FABP4 with protection from type 2 diabetes and cardiovascular 
disease (105). These studies suggest that FABP4 reduces lipid toxicity, perhaps by directing 
excess FAs to neutral lipid synthesis. 
The epithelial FABP (Fabp5) is highly expressed in differentiated keratinocytes, with 
lower levels of expression in heart and white adipocytes (106,107). Since many other lipid 
abnormalities result in dramatic skin phenotypes, it was surprising when FABP5 deficient mice 
were superficially normal and had only minor disruption of skin barrier function (108). Fabp6 is 
expressed mainly in the ileum of the small intestine (109). Knockout mice suggest that FABP6 is 
primarily important for the ileal absorption of bile acids from the lumen of the small intestine 
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into the portal circulation (110). Fabp7 is most highly expressed in neurons (111). Newborn 
Fabp7-/- mice had decreased docosahexaenoic acid in brains; older mice had increased 
arachidonic acid and palmitic acid in adult brains associated with anxious behavior (112). QTL 
analysis found an association with anxiety and schizophrenic behaviors in mice (113). Knockout 
of both Fabp7 and Fabp5 has implicated these genes in neural differentiation and brain 
development; it is unclear if this is related to their role in directing lipids to oxidation, 
phospholipid synthesis, or gene transcription (114,115). 
The first FA binding protein and transporter identified, known as the plasma membrane 
FABP, is better known as glutamate oxaloacetate transferase (GOT2) due to having 
aminotransferase activity  (116,117). This protein localizes to the plasma membrane, particularly 
in hepatocytes that have long-term alcohol exposure (118). Studies in cultured skeletal myocytes 
have implicated GOT2 as directing FFA to TG esterification (119,120). GOT2 can localize to 
both the plasma membrane and the mitochondria; however, studies in skeletal muscle of 
exercised rats suggest that it primarily transports FFA into the cell rather than into mitochondria 
(121).  
The identification of FA transporters and intracellular FA binding proteins has linked 
uptake of circulating lipids with specific intracellular fates, whether that is β-oxidation, 
esterification into TG, or transcriptional activation. Existing literature primarily focuses on the 
distinct roles of these proteins, and further investigation will likely elucidate how these proteins 
work in concert. 
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Lipid droplets and associated proteins 
The classical lipid droplet protein categorization has been according to the so-called PAT protein 
– perilipin, adipophilin, and TIP47. Recently, a uniform naming convention has been adopted 
(122). The most recent nomenclature and common aliases are listed in Table 2. 
Table 2 - Lipid droplet proteins  
Gene Aliases 
PLIN1 Perilipin, Lipid droplet associated protein, Perilipin A 
PLIN2 Adipophilin (ADFP), Adipose differentiation-related protein (ADRP) 
PLIN3 Cargo Selection protein TIP47, Mannose-6-phosphate receptor-binding protein 1 
PLIN4 Adipocyte protein S3-12 
PLIN5 Lipid droplet-associated protein PAT-1, Lipid storage droplet protein 5 (Lsdp5), Myocardial Lipid 
Droplet Protein (MLDP), Oxidative PAT protein (OXPAT) 
ABHD5 1-acylglycerol-3-phosphate O-acyltransferase, Abhydrolase domain-containing protein 5, Lipid 
droplet binding protein CGI-58 
CIDEA Cell death-inducing DFFA-like effector A 
CIDEB Cell death-inducing DFFA-like effector B 
CIDEC Cell death activator CIDE-C, fat-specific protein 27 (FSP27) 
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Adipocytes in WAT usually have a single large lipid droplet. As described previously, PLIN1 is 
the primary lipid droplet coat protein in WAT (123). When Plin1 was knocked out in mice, these 
animals consumed more food but were protected from weight gain; furthermore, knockout 
protected against obesity when crossed with the leptin-receptor deficient obese mice (124,125). 
These studies also implicated Plin1 as a regulator of TG degradation via hormone-sensitive 
lipase (HSL) – both as protecting the lipid droplet from lipolysis, but also in the activation of 
lipase activity. At the time of these studies, it was believed that HSL was the most important 
gene for TG lipolysis; later studies demonstrated that knockout of Hsl only partially reduced TG 
lipase activity and did not result in TG accretion in WAT. Therefore, Plin1 is implicated in both 
regulating HSL and the other major TG lipase – the subsequently described adipose triglyceride 
lipase (ATGL) (126,127). 
The second perilipin family member, Plin2, has been most extensively characterized in 
the liver. The most dramatic phenotype of Plin2-deficient mice was reduced hepatic TG content 
as well as protection from diet-induced fatty liver (128). These observations were attributed to a 
defect in lipid droplet biogenesis and a possible microsomal accumulation of TG. When crossed 
with obese leptin-deficient mice, these mice were somewhat protected from hepatic TG 
accumulation, about a 20% decrease (129). More dramatically, these obese mice lacking Plin2 
had improved insulin and glucose sensitivity. This was coupled with increased VLDL secretion. 
Later it was shown that Plin2 knockout mice on wild-type background were protected from diet-
induced obesity, probably due to redistribution and increased mitochondrial proliferation and 
thermogenesis in white adipocytes (130). These data suggest that Plin2 may play a role in 
extrahepatic tissues; these functions have yet to be described.  
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There have been no published Plin3 knockout mice; however, RNA interference targeting 
of Plin3 led to a reduction of hepatic TG contents and VLDL secretion (131). It is unclear why 
this occurred, and further studies are required to elucidate the molecular mechanism of Plin3 
regulation of lipid droplet formation, structure, and turnover. 
Plin4 is involved in lipid droplet biogenesis in white adipocytes. This protein is localized 
on the surface of lipid droplets, along with PLIN1 and ABHD5 (132). Although the highest 
levels of Plin4 expression are in white adipocytes, knockout animals displayed no overt adipose 
tissue phenotype, normal fat mass accretion, and no change in WAT lipolytic activity (133). 
However, these mice had an interesting cardiac phenotype – failure to accumulate TG lipid 
droplets after an overnight fast – probably due to decreased mRNA and protein of Plin5. It is 
unclear why Plin5 expression decreased in the hearts of these Plin4-/- mice. 
Plin5 is referred to as the oxidative lipid droplet protein, due to its high expression level in 
oxidative tissues like the heart, skeletal muscle, and BAT (134). PLIN5 is similar to PLIN1 in 
that it coats lipid droplets and translocates into the cytosol upon adrenergic stimulation (135). 
Unlike PLIN1, it also binds directly to both ATGL and the co-activator, ABHD5. As expected, 
Plin5 knockout mice had decreased TG in many oxidative tissues, and most notably failed to 
store lipid droplets during fasting (136). These hearts had increased lipid oxidation and 
eventually developed cardiac dysfunction as measured by fractional shortening. Two recent 
studies demonstrated cardiac steatosis in mice that specifically overexpress Plin5 in cardiac 
myocytes, most likely due to decreased intracellular TG lipolysis (137,138). 
Concurrent with the description of the Atgl knockout mouse, the co-activator abhydrolase 
domain containing 5 (Abhd5) was characterized (139). This protein is responsible for increasing 
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activity of ATGL (140). Loss of function mutations in this gene are associated with the neutral 
lipid storage disorder Chanarin-Dorfman syndrome, typified by TG accretion in many organs. In 
adipocytes, ABHD5 bound to PLIN1 moves off the lipid droplet upon adrenergic stimulation, 
which facilitates interaction with ATGL to stimulate increased lipolysis (Figure 2) (141). 
Knockout of this gene in mice resulted in early postnatal lethality and exhibited ichthyosis due to 
failure to produce skin wax lipids (142). More recently, a muscle-specific knockout of Abhd5 





Figure 2 - Adrenergic regulation of intracellular lipolysis 
 
Upon binding of adrenaline to the β–adrenergic receptor, adenylate cyclase (AC) is activated. 
This leads to the production of cyclic AMP (cAMP), which activates protein kinase A (PKA). 
PKA phosphorylates PLIN1, which leads to the release of the ATGL activator ABHD5. PKA 




In summary, lipid droplet proteins serve two primary functions – lipid droplet structure 
and regulation of lipase activity. Plin1 and Plin5 seem important for both of these roles, whereas 
Abhd5 is primarily important for regulation of lipase activity. Plin2 seems primarily important 
for lipid droplet structure and probably has some role in VLDL assembly and secretion. The 
exact functional roles of Plin3 and Plin4 are unclear. 
There are a number of other lipid droplet proteins, the cell death activator (CIDE) 
proteins – CIDEA, CIDEB, and CIDEC. Cidea is most highly expressed in the BAT, but there is 
detectable expression in the heart. Cidea knockout mice are lean and protected from diet-induced 
obesity; the authors stated that it was a negative regulator of BAT thermogenesis by suppressing 
UCP1 activity (144). Cideb deficiency resulted in ubiquitously increased lipid oxidation resulting 
in lower plasma TG and FFA, as well as low TG accumulation in other tissues and protection 
from diet induced obesity (145). There is no clear mechanism why Cideb deletion causes this 
phenotype; however, VLDL secretion was impaired during fasting in Cideb knockout mice 
(146,147). Cidec, better known as fat-specific protein 27 (Fsp27), is involved in promoting the 
accumulation of unilocular lipid droplets in white adipocytes; knockout mice had impaired white 
adipose tissue growth and exhibited multilocular lipid droplets and mitochondrial proliferation in 
white adipocytes (148). Furthermore, these mice were protected from diet-induced obesity and 
had normal glucose disposal and insulin tolerance. Later it was shown that CIDEC mediates the 
transfer of lipids from smaller to larger lipid droplets, which most likely explains the phenotype 
in the knockout mice (149,150). 
Most of the understanding of lipid droplet proteins comes from cultured cells or knockout 
animals. Future studies are critical to evaluate the role of these proteins and their interactions. 
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Most in vivo characterizations of these proteins rely on the overexpression and knockouts; thus it 
is critical to use innovative techniques to characterize their complex interplay. 
Lipid droplet synthesis and degradation 
Understanding intracellular lipid droplet accumulation and turnover in both liver and 
WAT is essential to understand how these organs regulate circulating lipids. The liver 
synthesizes FA and secretes TG and cholesteryl esters in TG-rich lipoproteins. The WAT has 
some ability to synthesize FAs, but primarily functions as a TG storage and FFA secretion organ.  
The liver is central to metabolism of all macronutrient classes. Excess dietary 
carbohydrates can be converted to acetyl-CoA and serve as a building block for the synthesis of 
new FAs. Furthermore, the liver has a tremendous capacity to take up circulating albumin-bound 
FFAs (151). The hepatic pool of FFAs is rapidly esterified into TGs. The liver can store some of 
these TGs, but the main role of the liver is to secrete apolipoprotein B-100 very-low density 
lipoproteins (VLDL). The assembly process of VLDL particles is similar to the assembly process 
of chylomicrons, where MTTP mediates the loading of TG molecules into a nascent apoB-100 
containing lipoprotein. These VLDL particles contain TGs as well as cholesteryl esters; in the 
post-prandial state these particles contain about 80% of circulating FA. Circulating VLDL-TG is 
hydrolyzed by LpL to release FAs for tissue uptake.   
The primary role of the WAT is to store excess calories as TG. The WAT is a major 
depot of CM lipolysis via LpL, leading to storage of dietary lipids. WAT LpL activity is 
increased in the fed state to facilitate the storage of excess dietary lipids (152,153). On the other 
hand, fasting decreases WAT lipoprotein lipase activity via the local secretion of AngPtl4, which 
inhibits LpL by breaking apart the catalytic dimer (35). Decreasing WAT lipoprotein lipase 
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activity during fasting is probably to facilitate a net flux of circulating TGs to tissues like the 
heart and skeletal muscle that need to maintain constant energy production, and to avoid futile 
cycling of lipids in and out of WAT. The critical role for LpL in the clearance of plasma TG is 
evident in humans who have genetic deficiencies that lead to familial hyperchylomicronemia 
(154,155).  
Intracellular lipolysis 
The CM- and VLDL-derived FFAs that are taken up in white adipocytes are then re-
esterified and are stored in a single large lipid droplet. Lipid droplet proteins and intracellular 
lipases control turnover of the lipid droplet. The primary lipid droplet protein in white adipocytes 
is perilipin (Plin) 1. This protein is responsible for both maintaining the structure of the lipid 
droplet and for regulating the activity of intracellular lipases (156). The recently described rate-
limiting intracellular lipase is ATGL, which primarily catalyzes the release of a single FFA from 
a TG molecule (127,139,140). The second enzyme in the lipolytic cascade is hormone-sensitive 
lipase (HSL), which yields a second FFA and a monoglyceride molecule. It should be noted that 
the enzyme activity termed “hormone-sensitive lipase” has been used in classic literature and in 
textbooks to represent the total intracellular lipolytic activity, and not just the activity of the 
enzyme HSL.  
For decades, intracellular lipolytic activity was attributed to the activity of HSL. HSL 
was cloned and identified to be stimulated by catecholamines and repressed by insulin, primarily 
through phosphorylation and dephosphorylation (157,158). However, when the HSL gene was 
knocked out in mice, there was only a partial decrease in adipose tissue lipolysis (126). It had 
been predicted that a failure to lipolyze intracellular TG would result in obesity; it did not. This 
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suggested the existence of another rate-limiting lipolytic enzyme. This other enzyme, adipose TG 
lipase (ATGL) was first identified from adipose tissue extracts as having TG lipase activity 
(159). This enzyme was knocked out in mice that then displayed the expected obesity phenotype, 
as well as ectopic lipid accumulation (127). In particular, these mice had increased cardiac TG 
accumulation associated with hypertrophy and heart dysfunction, leading to early mortality. 
The activity of ATGL and HSL enzymes in WAT are increased via β-adrenergic 
stimulation. Upon binding of catecholamines to the β-2 and β-3 adrenergic receptors in white 
adipocytes, a G-protein coupled receptor signaling cascade leads to the phosphorylation of 
PLIN1 by protein kinase A. The phosphorylation of PLIN1 leads to its release from the lipid 
droplet, allowing the lipolytic enzymes to access the TG (160,161). The release of PLIN1 also 
causes the release of a second protein, ABHD5, which can then co-activate ATGL (139). HSL is 
also phosphorylated by protein kinase A which activates its enzymatic activity (162). In concert, 
this leads to an approximate two-three fold increase in intracellular lipolysis, which has the net 
effect of increasing plasma FFAs (139). Conversely, insulin stimulation inhibits WAT lipolysis 
via the activation of phosphodiesterases, which inhibit the adrenergic signaling cascade 
(163,164).  
Transcriptional regulation of lipid metabolism 
The peroxisome proliferator-activated receptor (PPAR) family of proteins is of particular 
importance for transcriptional regulation of lipid metabolism. The PPARs have overlapping and 
distinct roles in transcriptional regulation of lipid metabolism (Figure 3). These are nuclear 
steroid hormone receptors that heterodimerize with the retinoid X receptor (RXR) to activate or 
repress transcription of genes, primarily those involved in lipid metabolism. 
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Figure 3 - PPARs: transcriptional control of lipid metabolism 
 
 
The first family member, PPARα, is primarily thought to drive transcription of genes 
involved in FA oxidation, such as Cpt1, acyl-CoA oxidase (Acox), and medium chain acyl-CoA 
dehydrogenase (Mcad). Not surprisingly, Ppara-/- mice have decreased FA oxidation (165). 
PPARα is particularly important in the transition from the postprandial to the fasted state, as it 
can increase the extrahepatic utilization of FAs and spare glucose utilization (166,167). Fibrate 
drugs activate PPARα and have the net effect of lowering plasma lipids; this is probably due to 
both increasing lipid oxidation as well as increasing lipid uptake by increasing LpL and Cd36 
(168). Furthermore, PPARα increased transcription of Plin2 and Plin5 in the heart and liver; this 
effect was abolished in PPARα knockout mice (169). The Atgl knockout mice, which have 
myocardial lipid accumulation associated with cardiac dysfunction and death, were treated and 
rescued by treatment with the PPARα agonist WY14,643 (170) suggesting that lipid droplet 
mobilization may be important for activation of PPARα. 
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Next, PPARδ activates transcription of a similar gene program to stimulate FA uptake 
and oxidation. While PPARα is thought to act primarily in the heart and liver, PPARδ is most 
important in the skeletal muscle (171) – knockout mice had reduced skeletal muscle β-oxidation, 
and stimulation with a PPARδ agonist increased skeletal muscle β-oxidation in two independent 
studies (172,173). Furthermore, treatment with a PPARδ agonist protected against weight gain in 
leptin-receptor deficient obese mice. It was later shown that overexpression of constitutively 
active PPARδ specifically in skeletal muscle dramatically boosted not only muscle oxidation, but 
dramatically improved exercise performance due to increased mitochondrial biogenesis and fiber 
type switching (174). 
PPARγ is perhaps best known as a transcription factor for stimulating adipogenesis (175) 
and is the target of thiazolidinediones (168). This member is most highly expressed in white 
adipocytes and drives expression of genes involved in the uptake, storage, and turnover of lipids, 
such as LpL, Cd36, Plin1, and Atgl (176,177). PPARγ knockout mice are embryonic lethal due to 
failure to correctly develop placenta; however, having a single null allele for PPARγ prevented 
diet induced obesity, at least partially due to impaired adipocyte proliferation and growth (178). 
In summary, the PPAR family of transcription factors seem to have distinct and 
overlapping roles in determining the expression of lipid metabolism genes 
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Figure 3). Each seems to be particularly important in certain organs, but may have important 
roles in particular conditions of stress. Many of the cardiac specific roles of PPARs are discussed 
in Chapter 2; in particular, how they may contribute to the development or amelioration of toxic 
lipid accumulation and heart dysfunction. 
The sterol regulatory element binding proteins (SREBPs) are another family of 
transcription factors that regulate lipid metabolism. SREBPs are endoplasmic reticulum 
membrane bound proteins that sense cellular lipid balance; when lipids are low, SREBP is 
cleaved by the SREBP cleavage activating protein (SCAP), at which point it can translocate to 
the nucleus to bind DNA and activate transcription of lipogenic genes (179). There are two 
distinct Srebp genes; splice-isoforms SREBP1a and SREBP1c primarily regulate transcription of 
genes involved in de novo lipogenesis, such as Acc1¸ Fasn, and Dgat1. SREBP2 drives 
transcription of genes to increase cellular cholesterol concentrations by activating transcription 
of genes such as HMG-CoA reductase (the rate-limiting enzyme for cholesterol synthesis) and 
the LDL receptor. Insulin signaling is believed to activate de novo lipogenesis in the liver 
primarily by activating SREBP1 (180,181). Although SREBP1 and 2 have been best 
characterized in how they regulate lipid metabolism in the liver, future studies may uncover 




Chapter 2: Lipid metabolism and toxicity in the heart 
This chapter has been published as a review in Cell Metabolism (182).  
Goldberg, I.J., Trent, C.M., Schulze, P.C. 
Introduction 
Although the heart is by far the most energy-requiring organ of the body, studies of 
cardiac lipid metabolism, especially in vivo, are relatively scarce compared with investigations in 
adipose tissue or liver. In adult fasting mammals, 60-80% of cardiac energy metabolism relies on 
the oxidation of FAs with glucose, lactate, and ketones providing substrates for the remainder 
(183). The adult heart, however, has the ability to switch to different substrates for ATP 
generation depending on feeding, hormonal status and overall nutritional supply as characterized 
by the Randle cycle (14). Of note, there are major species differences with mice relying more on 
glucose, lactate and ketone bodies, and much less on FAs (30-40% from fat) (184,185). The fetal 
heart operates under low oxygen pressure and primarily depends on glucose and lactate for ATP 
generation, whereas the adult heart utilizes FAs but conserves the ability to switch other 
substrates. Older animals and humans use relatively less FAs and more glucose.  
The heart avidly acquires lipids both from circulating FFAs and esterified FAs bound to 
lipoproteins (Figure 4). Observations made studying arterial venous differences in substrate 
concentrations showed that esterified FAs were a major source of lipids for the human heart 
(186).  More recent methods to study heart lipid metabolism have relied on tracers of FFAs in 
isolated perfused hearts. These studies quantify conversion of FFAs to CO2 and TCA cycle 
intermediates under a variety of experimental conditions. In vivo studies can assess the uptake 
and loss of tracers from the heart. Although the heart can synthesize lipoproteins as it expresses 
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both ApoB and microsomal TG transfer protein (187,188), under most circumstances, the heart 
probably does not re-secrete appreciable amounts of glucose or lipids, and the uptake should 
indicate oxidation plus a relatively small amount of substrate that is stored and a small amount of 
substrate used for structural requirements of the cell.  
In some situations, the heart adjusts to maintain lipid homeostasis. Increases in work load 
(189) and myocardial ischemia (190) cause a rapid switch from fat to glucose utilization for ATP 
generation. This finding has led to several animal studies showing that administration of 
compounds that reduce FA oxidation protect the heart from the consequences of ischemia and 
ischemia-reperfusion injury (189,190). This is presumed to be due to reduced oxygen 
requirements for non-FA substrates. Deleterious effects of cardiac ischemia could be due in part 
to excess cardiac lipid accumulation via the VLDL receptor (45). Similarly, in another mouse 
model of cardiomyocyte death adiponectin-induced activation of a ceramidase and reduction of 
ceramide was beneficial (191). Therefore, abnormal regulation of lipid uptake or its intracellular 
metabolism might play an important role in heart diseases other than metabolic dilated 
cardiomyopathy.   
An imbalance between FA uptake and oxidation leads to accumulation of long chain FAs 
that are incorporated into TG and phospholipids, as well as a multitude of other lipid subspecies. 
Although TG is the most easily detected, other lipids are more likely to be toxic. DAGs and 
ceramides are signaling lipids that are thought to be toxic when their intracellular concentrations 
are increased. Defective mitochondrial FA oxidation could lead to accumulation of medium 
chain acyl carnitines (192), another possible toxin. Finally, saturated long chain FAs, most 
 
33 
notably palmitate, are associated with toxicity in cells either because of their direct actions or 
because of their incorporation into phospholipids (193). 
Lipid uptake and turnover in the heart 
All tissues obtain lipids from FFAs associated with albumin, lipoproteins, and de novo 
synthesis (Figure 4A). Although de novo synthesis is thought to play a minor role in heart lipid 
metabolism, a recent study of deletion of FA synthase in heart showed that de novo synthesis is 
important to maintain cardiac function during aortic constriction and aging (194). Loss of 
lipoprotein lipase (LpL)-derived lipids leads to increased glucose uptake in mouse hearts (195). 
In humans, deficiency in CD36 is associated with increased glucose uptake (196). CD36 appears 
most important in the setting of lower concentrations of FFAs (58). Therefore, it is not surprising 
that when large amounts of FFA are generated during hydrolysis of large TG-rich lipoproteins 
like chylomicrons, heart uptake of lipids appears to be exclusive of this receptor (30). Lipolysis 
of lipoproteins is also a pathway for delivery of esterified core lipids such as cholesteryl esters 
and retinyl esters into the heart (30). 
Excess lipid, especially TG, beyond that needed for cellular structures and ATP 
generation is stored in lipid droplets (Figure 4B). Within the heart, there normally is little lipid 
droplet accumulation, suggesting that uptake and oxidation are finely regulated. Lipid droplets 
are found in hearts of patients with diabetes and metabolic syndrome (197-199) and in those of 
high-fat diet fed rodents and genetically altered mice (see below and Table 3). In addition, after 
an overnight fast, lipid droplets appear in the hearts of wild type mice (200).  
Lipid droplet protein makeup in the heart is different from that of adipocytes. In the heart, 
there is minimal expression of PLIN1. However, the other major lipid droplet proteins, PLIN2, 
 
34 
PLIN3, PLIN4, and PLIN5 are all expressed in the heart (201). Plin2 expression might be most 
upregulated in some forms of lipotoxicity and be important for non-toxic lipid storage (202). 
PLIN5 appears to regulate TG oxidation by approximating lipid droplets and mitochondria 
(203,204). Of these droplet proteins, only Plin2 has been deleted and chow-fed Plin2-/- mice do 
not have an obvious cardiac phenotype (128). Thus, knowledge of how and whether these 
proteins, and probably others, modulate heart lipid accumulation and TG oxidation is likely to be 
forthcoming. 
Lipid droplet turnover is regulated by lipid droplet associated proteins, intracellular 
lipases, and acyltransferases (205). Cardiac myocytes and skeletal myocytes have similar 
regulatory pathways that govern lipid metabolism. Lipid droplet TG can be hydrolyzed by ATGL 
and HSL, both of which are expressed in the heart. In the adipose tissue, insulin inhibits 
lipolysis, whereas catecholamines, thyroid hormone, and glucagon stimulate lipolysis. Whether 
similar regulation occurs in the heart is not known at present.  
The roles of lipolytic enzymes in the heart have been studied using genetically modified 
mice (206). Lipid droplet accumulation in overnight fasting mice is prevented by overexpression 
of HSL (207). In the total HSL knockout mouse, cardiac TG lipase activity was decreased, but 
cardiac TG was not dramatically changed, and there was no overt cardiac phenotype (126). In 
contrast, Atgl-/- mice have markedly reduced cardiac TG lipase activity, massive lipid 
accumulation, and severe cardiomyopathy (127). In part, this is likely due to a defect in the 
hydrolysis of TG that the heart stores for potential energy (208). Treatment of Atgl-/- mice with a 
PPARα agonist corrected the cardiac phenotype (170). Therefore, the excess accumulation of TG 
in the Atgl-/- hearts was at least partially due to increased lipid storage secondary to defective FA 
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oxidation. A less dramatic phenotype but one also associated with decreased FA oxidation 
activation occurred with cardiac deletion of Acsl1 (4). This study and another from this group (3) 
suggest that PPAR activation is via a product of the ACSL reaction. 
Recent studies have elucidated the role of autophagy in hepatic TG lipolysis. In the 
rodent heart, autophagy has been investigated as a stress response mechanism in myocardial 
infarction and pressure induced cardiac hypertrophy. Fasting induces autophagy in the heart 
(209), yet characterization of autophagy in the heart has not focused on lipid metabolic 
derangements. Inducible heart-specific autophagy knockouts develop cardiomyopathy (210); 
whether this is associated with increased lipid accumulation, as has been found in other organs 




Figure 4 - Cartoon of cardiac lipid metabolism 
 
A. FAs esterified as triacylglycerol (TG) within lipoproteins require hydrolysis by lipoprotein lipase 
(LpL) associated with proteoglycans and GPIHBP1 on the luminal surface of endothelial cells. 
ANGPTL4 is an LpL inhibitor. FFAs associated with albumin likely are internalized by membrane 
transporters such as CD36. These lipids must cross the endothelial barrier; how this occurs is unclear.  B. 
Within the cardiomyocytes the FAs are esterified to CoA and either stored in the LD or used for energy. 
At least four lipid droplet proteins (PLINs) are expressed in the heart. The lipid droplet supplies some 
oxidized FAs via the actions of adipose TG lipase ATGL and HSL. CGI58 is the ATGL co-activator. 
ATGL and LpL actions both provide ligands for PPAR activation.   
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Creation of cardiac lipotoxicity in mice  
A number of reasons for the association between diabetes and heart dysfunction in the absence of 
underlying vascular disease have been proposed; one of these is excess accumulation of lipids in 
cardiomyocytes (212). This possible cause of cardiomyopathy has been modeled by creating 
genetically modified animals in which lipid accumulation without generalized metabolic 
derangements leads to contractile impairment (Figure 5). These animals have an imbalance 
between lipid uptake and oxidation due to either increased lipid uptake or decreased oxidation. 
Increased uptake of circulating FFAs or lipoprotein-derived lipids as occurs with transgenic 
expression of LpL (213,214) leads to reduced heart function. Transgenic mice with 
cardiomyocyte specific expression of FATP1 (215) and ACSL1 (216) are thought to have 
increased FFA uptake or trapping in the heart leading to heart failure. PPAR transcription factors 
drive FA oxidation; however, the increased lipoprotein-lipid uptake in PPARα transgenic mice 
(217) must exceed the increased FA oxidation found in this model because the hearts have 
excess stored lipids. Cardiomyocyte PPARγ overexpression leads to a similar phenotype (202). 
Surprisingly, PPARδ expression does not lead to cardiac dysfunction or toxicity (218), 
presumably because upregulation of the LpL inhibitor ANGPTL4 prevents excess lipid uptake 
(219).  
LpL is the key enzyme for distribution of circulating lipids between organs. Perhaps the 
most clinically relevant model of cardiac lipotoxicity is one created by accident. Wang et al. 
deleted LpL using a skeletal muscle specific promoter (49). The mice were meant to model 
physically inactive humans who also have reduced muscle LpL and FA oxidation. These mice 
have increased insulin sensitivity in skeletal muscle, as would be expected with reduced FA 
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uptake, but develop insulin resistance in the heart, often a precursor of eventual heart 
dysfunction.  
Reduced lipid oxidation can also lead to lipid accumulation and cardiomyopathy. This 
occurs with cardiac specific knockout of PPARδ (220) and a cardiac LpL transgene crossed onto 
the Ppara-/- background (214). Similarly, heart dysfunction with excess lipid accumulation is 
found when heart-specific GLUT1 overexpressing mice are placed on a high fat diet (221). In 
contrast, when these animals eat chow their function is improved in the presence of hypertension 
(222). Therefore, in some situations, dietary driven lipid uptake – a likely accompaniment of our 
western diet – needs to be added to create a lipotoxic environment. 
Perhaps of most interest for understanding heart lipid metabolism and toxicity are the 
situations where reduced FA oxidation does not lead to lipid accumulation. In many cases, the 
reason for this has not been investigated, but we would presume that there is a compensation, 
such as a reduction in lipid uptake. This occurs with genetic or pharmacologic deficiency of 
DGAT1, which markedly reduces CD36 expression (223). Pharmacologic FA oxidation 
inhibitors proposed for reduction of ischemia (190) and genetically engineered defects in FA 
oxidation defects (224) would be expected to also create cardiac lipid accumulation and toxicity. 
That this does not occur indicates the existence of some processes that balance reduced oxidation 
or that lead to non-toxic lipid storage.  
Lipid stores and the causes of toxicity 
Although the most obvious and easiest to measure accumulated lipid is TG, TG itself 
might not be toxic. Consistent with cellular studies (225), several experimental situations have 
dissociated TG accumulation from toxicity. Total body knockout of HSL was associated with 
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more re-feeding TG accumulation, but no toxicity (226). A cross of the PPARγ transgene onto 
the  
Ppara-/- background corrected toxicity without reducing heart TG, ceramide or DAGs, but 
redistributed the lipids into larger droplets (227). 
 Although the preferred energy substrate for the heart is FA, a case has been made that 
excess reliance on FA oxidation is harmful, even under non-ischemic conditions. Some 
experimental data suggest the opposite. High fat diets, which usually increase reliance of FA 
oxidation, may be beneficial in the setting of non-ischemic heart failure (228). Increased FA 
oxidation, has been found with a Pparγ transgene crossed onto the Ppara-/- background (227), 
Dgat1 transgenic expression (229), and most recently with PPARα agonist treatment of Atgl-/- 
mice (170) all of which improve heart failure.  
Heart lipid content can also be increased by non-genetic means. While in some ways 
these models may more closely reflect human pathology, they suffer from the many other 
systemic effects of over-nutrition or diabetes. In addition, the heart phenotypes are relatively 
mild compared to those found with genetic modifications. Mice fed a high fat diet rapidly 
develop cardiac insulin resistance, suggesting that lipid accumulation rapidly causes changes in 
heart metabolism allowing it to rely more on FAs as its fuel (230). However, the effects of high 
fat on cardiac function are mixed. Hypertensive rats fed a 60% fat diet had less left ventricular 
hypertrophy and systolic dysfunction than animals fed 10% fat (228). Similarly, rats fed a high-
fat diet appeared to compensate by increasing FA oxidation, whereas those eating a lower fat but 
higher carbohydrate western diet developed dysfunction (231). Not all fats are equal. Saturated 
FA-rich diets alone increased cardiomyocyte apoptosis, perhaps due to accumulation of ceramide 
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(232). In contrast, medium chain FAs are protective against cardiac dysfunction in some 
situations (233,234). 
Other pharmacologic and genetic alterations change heart TG content. Using oxfenicine 
to block CPT-1, mice fed a diet enriched in long-chain saturated FA accumulated TG, but had no 
changes in left ventricular dimensions or systolic function, while PPAR-regulated genes were 
upregulated (235). Ob/ob and db/db mice have increased heart FA oxidation that develops prior 
to hyperglycemia (236). Eventually these mice develop decreased contractile function (237).  
Correction of lipotoxic heart disease 
A role of animal models is to test interventions that might be beneficial in human disease. 
Genetic approaches define targets, which might be amenable to pharmacologic or dietary 
interventions. Although a common underlying theme of lipotoxic cardiomyopathy is that it is 
created via an alteration in lipid metabolism, a single underlying toxic lipid species might not be 
causative in all case. Thus, interventions in one model might not prove to be beneficial in 
another. Similarly, the genetic and dietary variation amongst humans might also lead to multiple 
causes of cardiomyopathy associated with lipid accumulation.  
Altering the amount or type of FAs acquired by the heart will prevent toxicity both in 
genetic and dietary models of lipid toxicity. Deletion of either CD36 or LpL corrected the 
cardiac toxicity associated with cardiomyocyte overexpression of PPARα (217,238). CD36 
deletion was also reported to improve heart function in aged mice that were eating a diet 
enriched in medium chain FAs (239). Medium chain FA-rich diets were also beneficial in 
PPARα transgenic mice (240), presumably because of a reduction in saturated long chain fat-
enriched lipid accumulation. Other methods to reduce heart lipid content may also correct or 
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prevent toxicity (Table 3). The approaches to do that have included transgenic expression of 
HSL to increase lipolysis of stored lipids (241), reduced expression glycerol-3-phosphate 
acyltransferase-1 to decrease TG accumulation (242), and overexpression of ApoB to increase 
cardiac lipid secretion (243) .      
A targeted approach to modify one lipid species would seem to be an ideal way to both 
treat the disease and define the toxic lipid species. Such an approach was taken by reducing 
ceramide concentrations in LpL-overexpressing mice using the serine palmitoyl transferase 
inhibitor myriocin and SPT deficient mice (244). A similar attempt to modify a specific toxic 
lipid, DAG was attempted by overexpressing DGAT1 in cardiomyocytes. Although this 
intervention reduced DAG concentrations and heart dysfunction, ceramide was also reduced 
(229). This study suggests that alteration of a single lipid species in the heart might be difficult 




Table 3 - Correction of cardiac lipotoxicity 
  








MHC-FATP1 (215)   
Heart specific PPARδ 
knockout (220)   
MHC-PPARα (247) 
X heart specific LpL 
knockout 
X CD36-/- 




MHC-PPARγ (202) X PPARα knockout (227) 
Leptin deficiency (ob/ob) (248) (249) Leptin Infusion (249) 
ATGL knockout (140) PPARα agonists (170) 
MHC-LpLGPI (213) Ceramide synthesis inhibition (244) 
MHC-LPL X  
Ppara-/- (214)   
MHC-GLUT1 on HFD (221)   
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Figure 5 - Correcting cardiac lipotoxicity 
 
Genetically modified mice have been created that have either increased lipid uptake or decreased 
oxidation. Uptake occurs via the cell surface molecules lipoprotein lipase (LpL) and perhaps the 
FA transporter CD36 and/or FATPs. More FAs are “trapped” by complexing to CoA. Stored TG 
accumulates with defective hydrolysis due to deletion of ATGL. Two interventions, loss of 
PPARδ and high fat feeding in mice overexpressing Glut1, lead to reduced lipid oxidation. 
Transgenic expression of PPARα and PPARγ, which induce lipid oxidation genes, also cause 




Although lipid-induced cardiac toxicity clearly can be created, a number of clinical and 
experimental issues await clarification. We do not know about the exact clinical implications of 
this pathophysiologic phenomenon. Is it really a primary cause of cardiac dysfunction in patients 
with type 2 diabetes and metabolic syndrome? If so, does this occur because of unregulated 
cardiac uptake of FAs or reduced FA oxidation? If the latter, one could then postulate that in the 
setting of ischemia and afterload-induced heart failure, reduced FA oxidation should also 
promote accumulation of toxic lipids. Alternatively, as has been postulated in ischemia, does a 
disproportionate use of FAs create toxicity? Which lipids are toxic and which pathways are 
induced that lead to cellular dysfunction? A marriage of human and animal experimentation 




Chapter 3: Lipoprotein lipase activity is required for 
cardiac lipid droplet production 
This chapter has been published in the Journal of Lipid Research (250).  
Chad M. Trent; Shuiqing Yu; Yunying Hu; Nathan Skoller; Lesley A. Huggins; Shunichi 
Homma; Ira J. Goldberg 
Abstract  
The rodent heart accumulates TG and lipid droplets during fasting. The sources of heart lipids 
could be either FFAs liberated from adipose tissue or FAs from lipoprotein-associated TG via the 
action of lipoprotein lipase (LpL). Because circulating concentrations of FFAs increase during 
fasting, it has been assumed that albumin transported FFAs are the source of lipid within heart 
lipid droplets. We studied mice with three genetic mutations: peroxisomal proliferator-activated 
receptor alpha deficiency, cluster of differentiation (CD) 36 deficiency, and heart specific LpL 
deletion. All three genetically altered mice had defective accumulation of lipid droplet TG. 
Moreover, hearts from mice treated with poloxamer 407, an inhibitor of lipoprotein TG lipolysis, 
also failed to accumulate TG, despite increased uptake of FFAs. TG storage did not impair 
maximal cardiac function as measured by stress echocardiography. Thus, LpL hydrolysis of 
circulating lipoproteins is required for the accumulation of lipids in the heart of fasting mice.  
Introduction 
The human heart will accumulate TG in lipid droplets in disease states such as obesity and 
diabetes. Whether TG storage directly leads to reduced heart function, i.e. lipotoxicity (182,251), 
or is a marker for accumulation of other toxic lipids is unclear. Evidence suggesting that stored 
TG in cardiomyocytes is not always toxic has come from experiments in genetically modified 
 
46 
mice. For instance, overexpression of the final enzyme in TG synthesis, DGAT1 in 
cardiomyocytes increased TG stores but reduced accumulation of toxic lipids and did not reduce 
heart function (229). Overexpression of DGAT1 in skeletal muscle also increased TG storage in 
mice with diet-induced obesity and mimicked the “athlete’s paradox” observed in endurance-
trained humans; skeletal muscle DGAT1 transgenic mice had increased FA oxidation and 
improved insulin sensitivity (252). In contrast, increased TG accumulation in the human heart 
correlates with reduced heart function (197,199). Moreover, greater TG stores are often 
associated with greater FA oxidation and greater injury during ischemia/reperfusion in isolated 
perfused hearts (190). Thus, the role of TG stores in the heart is unclear. 
Even the substrate used for heart TG production has not been established. One 
physiologic stimulus that causes lipid accumulation in mouse hearts is prolonged fasting (200). 
Since starvation is a threat to survival, lipid accumulation in the heart may be an adaptation to 
accommodate future energetic demands, to protect the heart from lipotoxicity, or to do both. 
Understanding the features of this adaptation may provide insight into mechanisms that drive 
lipid accumulation under physiologic and pathological conditions. During fasting, animals rely 
exclusively on stored energy. While the liver produces and releases glucose under fasting 
conditions, this is insufficient to meet the energetic demands of the body (253). Adipose tissue is 
the major storage depot for energy in the form of TG. During the fed state, dietary glucose 
stimulates insulin secretion, which simultaneously promotes glucose utilization and lipid storage. 
During fasting, circulating insulin concentrations fall while glucagon and catecholamines 
increase. This shift in the hormonal milieu leads to an activation of glycogenolysis in the skeletal 
muscle and liver and lipolysis in the adipose tissue. However, prolonged fasting will deplete 
glycogen stores and thus the energy demands of peripheral tissues must rely on both the liver – 
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to secrete glucose, ketone bodies, and TG – and the adipose tissue – to secrete FFAs and 
glycerol. Adipose tissue secreted glycerol, as well as lactate secreted from both adipose tissue 
and muscle, are taken up by the liver and used as substrates for gluconeogenesis. 
We tested whether reduced FA oxidation increased fasting-induced TG accumulation in 
the heart. To do this we studied peroxisomal proliferator-activated receptor (PPAR) α knockout 
mice. Surprisingly, we found that fasted Ppara-/- mice had no lipid droplet accumulation in 
hearts and had a marked reduction in mRNA levels of the FA transporter cluster of 
differentiation (CD) 36 as well as lipoprotein lipase (LpL) (254,255); LpL is required for heart 
uptake of FFAs from lipoprotein TG. We then assessed the specific roles of CD36 and LpL in 
heart TG accumulation. Our data show that LpL activity is required for the accumulation of heart 
lipid droplets. In addition, we demonstrated that lipid droplet accumulation does not affect 
maximal systolic function of the heart.  
Materials and Methods 
Animals and Fasting We used 3-4 month old male C57BL/6 mice, Ppara-/- mice (166), Cd36-/- 
mice (55), floxed LpL mice (LpLflox/flox) and heart specific LpL knockout (hLpL0) mice (48). 
Mice were fed a normal chow diet. C57BL/6 mice were used as controls for both Ppara-/- and 
Cd36-/- mice and LpLflox/flox littermates served as controls for the hLpL0 studies. Mice of each 
genotype were divided into two groups. One group was subjected to a 16-hour overnight fast and 
the other group was fed ad libitum over the same time period. These mice were then sacrificed 
with a lethal injection of 100 mg/kg ketamine and 10 mg/kg xylazine. All procedures were 
approved by the Columbia University Institutional Animal Care and Use Committee. 
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Tissue Collection A ventral incision was made after administration of 10 mg/kg ketamine-
xylazine. The left ventricle of the heart was perfused with 10 ml of PBS or until the liver 
appeared blanched. Tissues were rapidly removed and frozen in liquid nitrogen. Heart pieces 
were embedded into Tissue-Tek O.C.T. compound (Sakura, USA) for histology.  
Measurement of Plasma Lipids and Glucose 200 µL of blood was drawn from each animal 
after administration of ketamine/xylazine and then centrifuged at 2,000 rpm for 10 minutes to 
obtain plasma. Plasma was utilized for measurement of TG, FFA, and glucose by colorimetric 
assays. TG measurements were made using the Thermo Scientific Infinity assay (Thermo 
Scientific, USA), FFA was measured using the Wako NEFA kit, and plasma glucose was 
measured using the Wako Autokit Glucose kit (Wako Life Sciences, USA). 
Lipid Extraction from Tissues The lipid extraction protocol was adapted from the Folch 
method (256). Approximately 100 mg of ventricular tissue in 1 mL of PBS were homogenized 
using stainless steel beads for 1 minute in a bead beater homogenizer. From each sample, 50 µL 
were removed for protein analysis and 3 ml of 2:1 chloroform: methanol was added to the rest 
and vortexed. Samples were then centrifuged for 10 minutes at 3000 rpm at 4°C. The lower, 
organic phase was then collected and dried under nitrogen gas. The dried lipid was then 
dissolved in 500 µL of 1% Triton-X 100 in chloroform, further dried and then dissolved in 100µl 
of double distilled water. 
Lipid and Protein Measurements of Tissues The sample of tissue lysate retained from the lipid 
extraction protocol was assayed for protein content using Bradford reagent (Bio-Rad, USA) 
following the instructions of the manufacturer. Using the tissue lipid extract, assays for TG and 
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FFA were performed as previously described for plasma lipids. Lipid measurements were 
normalized to protein content or tissue weight. 
Microscopy for Cardiac Lipid Visualization Heart pieces were embedded in Tissue-Tek 
O.C.T. compound (Sakura, USA) and then air-dried and fixed with formalin. Sections were 
washed with distilled water and isopropanol. Lipids were then stained with Oil Red O for 18 
minutes, washed with isopropanol and distilled water, and then counterstained with hematoxylin. 
Slides were once again washed with distilled water and covered with clear nail polish. Images 
were taken using a Leica DMLB microscope and digital camera. Shown are representative 
images obtained from 5 animals of each genotype.  
Glycogen Staining and Quantification Periodic acid – Schiff reagent (PAS) staining was used 
to demonstrate heart glycogen. Sections of OCT embedded hearts were placed in 10% neutral 
buffered formalin. Ventricular tissue sections were fixed in methanol for 10 minutes and stained 
with PAS (Poly Scientific), hematoxylin, and eosin. Images were taken using a Leica DMLB 
microscope and digital camera. 4-5 mouse hearts were used for each genotypes and for each 
feeding condition, and several representative images were captured for each mouse. 
Glycogen was also measured by extracting total insoluble carbohydrates and digesting with 
amyloglucosidase, and free glucose was then measured and reported as ratio to tissue weight 
used for measurement as previously described (257). Ventricular tissue was hydrolyzed in 300 
µL of 5.4 M KOH in a 100oC water bath for 30 minutes. Then, 100 µL 1 M Na2SO4 and 800 µL 
of 100% ethanol were added to each sample. Samples were boiled for 5 minutes and then 
centrifuged at 10,000 G for 5 minutes. The glycogen pellet was dissolved in 200 µL water and 
ethanol precipitation was performed twice with addition of 800 µL of 100% ethanol. Finally, the 
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glycogen pellet was dissolved in 200 µL of 60 units/mL amyloglucosidase (Sigma, USA) in 0.2 
M sodium acetate (pH 4.8) and incubated for 3 hours at 40oC. Each sample was diluted 5X and 
glucose concentration was measured using the Wako Autokit Glucose kit (Wako Life Sciences, 
USA). 
Cardiac Gene Expression Total RNA was purified from a 30-50 mg piece of heart ventricular 
tissue using the TRIzol reagent (Invitrogen, USA) according to the instructions of the 
manufacturer. cDNA was synthesized using the SuperScript III First-Strand Synthesis SuperMix 
(Invitrogen, USA) and quantitative real-time PCR was performed with SYBR Green PCR Core 
Reagents (Agilent Technologies, USA) using an Mx3000 sequence detection system (Stratagene, 
La Jolla, CA). Genes of interest were normalized against 18s rRNA. Primer sequences are listed 
in Table 4. 
Western Blotting Hearts were excised as previously described. Approximately 20 mg of 
ventricular tissue was homogenized in RIPA buffer containing protease inhibitor cocktail 
(Sigma-Aldrich, USA). 25 µg of protein extract was applied to SDS-PAGE and transferred onto 
PVDF membranes. Antibodies for PLIN2 and PLIN5 were obtained from Santa Cruz 
Biotechnology (PLIN2, β-actin) and American Research Products (PLIN5). Band density 
measurements were made using ImageJ software. PLIN2 and PLIN5 band densities were 
normalized to β-actin band density. 
Stress Echocardiography Echocardiography was performed on 3-4 month old male Cd36+/+ 
(wild type), Cd36-/-, LpLflox/flox, and hLpL0 mice fasted for 16 hours. Two-dimensional 
echocardiography was performed using a high-resolution imaging system with a 30-MHz 
imaging transducer (Vevo 770; VisualSonics, USA) in unconscious mice. The mice were 
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anesthetized with 1.5-2% isoflurane and thereafter maintained on 0.5% isoflurane throughout the 
procedure. Care was taken to minimize sedation by monitoring the heart rate of the mice; 
measurements were only made after the heart rate was 400-500 beats per minute. Two-
dimensional echocardiographic images were obtained using short-axis views at the level of 
papillary muscles, and each parameter was measured using M-mode view. Images were analyzed 
offline by a researcher blinded to the murine genotype. Left ventricular end-diastolic dimension 
(LVEDd) and left ventricular end-systolic dimension (LVEDs) were measured. Percentage 
fractional shortening (FS), which quantifies contraction of the ventricular wall and is an 
indication of muscle function, was calculated as FS = ([LVEDd − LVEDs] / LVEDd) × 100. To 
assess stress response 0.3-mg/kg isoproterenol (Sigma-Aldrich, USA) was administered 
intraperitoneally. Successful administration of drug was confirmed by observation of increased 
heart rate. 
Pharmacologic Inhibition of LpL Poloxamer 407 (P407) was prepared in PBS as previously 
described (258). Mice were injected intraperitoneally with 1 mg/g body weight of P407 and then 
fasted for 16 hours. Control mice were injected with an equivalent volume of PBS. Mice were 
killed and analyzed as previously described. 
In vivo Assessment of Cardiac Glucose and FFA Uptake FFA and glucose uptake was 
assessed in mice that were injected with PBS or P407 and then fasted for 16 hours. [9,10-3H(N)] 
oleate (PerkinElmer Life Sciences) was complexed to 6% FA-free bovine serum albumin 
(Sigma). Mice were injected intravenously with 1 µCi [9,10-3H(N)] oleate-bovine serum albumin 
and blood was collected at 0.5, 1, 3, and 5 minutes after injection. Five minutes after injection, 
the left ventricle of the heart was perfused with 10 ml of PBS by cardiac puncture and tissues 
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were excised. Tissue was homogenized in PBS and radioactive counts were measured. Basal 
glucose uptake was measured in hearts following an intravenous administration of 2.5 µCi of 2-
deoxy-D-[1-14C] glucose (PerkinElmer Life Sciences). Blood was collected 2, 30, and 60 
minutes following injection. At 60 minutes, hearts were perfused with PBS, tissues excised, and 
radioactive counts measured. For all turnover studies, radioactivity per gram of tissue was 
normalized to the respective 30 second or 2 minute plasma counts (injected dose).  
Density Ultracentrifugation of Plasma Approximately 60 µL of mouse plasma was separated 
by density ultracentrifugation as previously described (259). Briefly, 60 µL of plasma was 
underlayed to 60 µL of 1.006 g/mL saline solution in an ultracentrifuge tube. Each tube was 
centrifuged at 70,000 RPM at 12oC for 3 hours. The supernatant was removed and contains 
VLDL. Next, 60 µL of 1.12 g/mL KBr solution was added to the remaining infranatant. This was 
centrifuged at 70,000 RPM at 12oC for 12 hours. The supernatant was removed and contains 
LDL. The infranatant was removed and 60 µL of 1.34 g/mL mixture of KBr and NaCl added. 
This was centrifuged at 70,000 RPM at 12oC for 12 hours. The supernatant was removed and 
contains HDL. The remaining infranatant contains all other plasma proteins, including FFA 
complexed to albumin. Counts of [3H]-oleate was measured in each fraction and reported as 
percentage of total counts measured.  
Ceramide Quantification  
Ceramides were measured as previously described (260). All solvents for sample extraction and 
LC/MS were LC/MS grade (or LC grade when LC/MS grade was not available) and were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ceramide standards were purchased 
from Avanti Polar Lipid, Inc. (Alabaster, AL, USA). Samples were processed as described 
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previously with modification (2). Briefly, 3 ml of the methanol containing 20 µl of a 2 µM 
internal standard mixture (Avanti LM-6002, containing C12 and C25 ceramides) were added to 
100 µl aqueous of heart homogenate containing 10 mg heart tissue in a clean glass tube, vortex-
mixed and allowed equilibrate for 10 minutes on ice. Then the mixture was vortexed again and 
centrifuged at 3,000g for 10 minutes at 4 C degree. The organic upper phase was transferred to a 
second clean glass tube and evaporated under nitrogen.  The extracted lipids were reconstituted 
in 300 µl of methanol: acetonitrile (v:v=1:1) and transferred to LC/MS autosampler vials 
(Waters, P/N 600000670CV) for evaporation under nitrogen. The lipid extract was finally 
reconstituted in 50 µl methanol for injection. All LC/MS/MS running were carried out on a 
Waters Xevo TQ MS ACQUITY UPLC system (Waters, Milford, MA) controlled by Mass Lynx 
Software version 4. 1. The sample was maintained at 4°C in the autosampler and 5 µl was loaded 
onto a Waters ACQUITY UPLC BEH Phenyl column (3 mm inner diameter × 100 mm with 1.7 
µm particles), preceded by a 2.1 × 5 mm guard column containing the same packing. The UPLC 
flow rate was continuously 300 µl/min in a binary gradient mode with methanol and water both 
containing 0.2% formic acid and 1 mM ammonium formate.  Positive ESI-MS/MS mass 
spectrometry was performed to identify ceramide species of interest. Different species were 
confirmed by comparing the retention times of experimental compounds with those of authentic 
standards. Concentrations of ceramides in the samples were quantified by comparing integrated 
peak areas for those of each ceramide against those of known amounts of purified standards. 
Loss during extraction was accounted for by adjusting for the recovery of the internal standard 
added before extraction. 
Triglyceride lipase activity assay TG lipase activity was performed as described (137,143). 
Tissue lysates were prepared in solution A (0.25 M sucrose, 1 mM EDTA, 1 mM DTT, pH 7.0, 1 
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µg/mL pepstatin, 2 µg/mL antipain, and 20 µg/mL leupeptin). Protein concentration was 
measured with Bradford reagent, and 50 µg of protein was used for each assay. Micelles were 
prepared by sonication in 0.1 M potassium phosphate buffer (pH 7.0) with 1.67 mM triolein, 10 
µCi [9,10-3H(N)] triolein/mL (Perkin-Elmer), 142.5 mM phosphatidylcholine, and 47.5 mM 
phosphatidylinositol. FA free BSA was added to the micelles at 2% concentration 
(weight/volume). 100 µL of radiolabeled substrate was incubated with diluted protein lysates for 
1 hour at 37oC in a 125 RPM shaking incubator. The reaction was stopped by the addition of 
3.25 mL mixture of methanol, chloroform, and n-heptanes (10:9:7, volume). FAs were extracted 
by addition of 1 mL of 0.1 M potassium carbonate, 0.1 M boric acid (pH 10.5) and centrifugation 
at 3000 RPM for 10 minutes. 200 µL of the aqueous phase were counted for radioactivity. 
Statistical Analysis Data are expressed as mean + SE. Data were analyzed by the use of 




Table 4 - Primer sequences for "LpL activity is required for cardiac lipid droplet 
production" 
Gene Forward primer Reverse primer 
18s 5'-CCATCCAATCGGTAGTAGCG-3' 5'-GTAACCCGTTGAACCCCATT-3' 
Abhd5 5'-TGACAGTGATGCGGAAGAAG-3' 5'-AGATCTGGTCGCTCAGGAAA-3' 
Acc2 5'-TGGAGTCCATCTTCCTGTCC-3' 5'-GGACGCCATACAGACAACCT-3' 
Acox1 5'-GGATGGTAGTCCGGAGAACA-3' 5'-AGTCTGGATCGTTCAGAATCAAG-3' 
Atgl 5'-CGCCTTGCTGAGAATCACCAT-3' 5'-AGTGAGTGGCTGGTGAAAGGT-3' 
Cd36 5'-TGTGTTTGGAGGCATTCTCA-3' 5'-TGGGTTTTGCACATCAAAGA-3' 
Cpt1b 5'-TCTAGGCAATGCCGTTCAC-3' 5'-GAGCACATGGGCACCATAC-3' 
Dgat1 5'-GTGCACAAGTGGTGCATCAG-3' 5'-CAGTGGGATCTGAGCCATCA-3' 
Dgat2 5'-CTGTCACCTGGCTCAACAGA-3' 5'-TATCAGCCAGCAGTCTGTGC-3' 
Fabp3 5'-GACGAGGTGACAGCAGATGA-3' 5'-TGCCATGAGTGAGAGTCAGG-3' 
Fasn 5'-TTGCTGGCACTACAGAATGC-3' 5'-AACAGCCTCAGAGCGACAAT-3' 
Fatp6 5'-GGTCACGGTGCTGGATAAGT-3' 5'-CGAGGAGTGGTTCAGGAGAG-3' 
Glut1 5'-GCTGTGCTTATGGGCTTCTC-3' 5'-CACATACATGGGCACAAAGC-3' 
Glut4 5'-ACTCTTGCCACACAGGCTCT-3' 5'-CCTTGCCCTGTCAGGTATGT-3' 
Got2 5'-GTTGAAATGGGACCTCCAGA-3' 5'-GGGCAGGTATTCTTTGTCCA-3' 
Lpl 5'-GCTGGTGGGAAATGATGTG-3' 5'-TGGACGTTGTCTAGGGGGTA-3' 
Pdk4 5'-TTCTCGGAGTCTGGAATGCT-3' 5'-GCTCTAGCCGAACACGAATC-3' 
Plin2 5'-CTACGACGACACCGAT-3' 5'-CATTGCGGAATACGGAG-3' 
Plin5 5'-GTGATCAGACAGCTCAGGACCCT-3' 5'-CGATTCACCACATTCTGCTGG-3' 
Scd1 5'-TGCGATACACTCTGGTGCTC-3' 5'-TAGTCGAAGGGGAAGGTGTG-3' 





Fasted Ppara-/- mice do not store lipids in the heart  
We first assessed heart lipid storage in Ppara-/- mice. We fasted Ppara+/+ (wild type) and Ppara-/- 
mice overnight for 16 hours. Fasting increased plasma FFA 2-fold in Ppara+/+ mice and 3-fold in 
Ppara-/- mice, but had no significant effect on plasma TG (Figure 6). Plasma glucose decreased 
approximately 30% in fasted Ppara+/+ mice and approximately 60% in fasted Ppara-/- mice. 
Fasting increased heart TG 5-fold in Ppara+/+ mice, but there was no significant TG 
accumulation in Ppara-/- mice (Figure 7). Heart FAs increased approximately 30% in Ppara+/+ 
mice, but were not increased in Ppara-/- mice (Figure 7). Fasted Ppara+/+ mice had increased Oil 
Red O staining, but Ppara-/- mice had minimal staining (Figure 8).  
Figure 6 - Plasma biochemistry of fed and fasted Ppara+/+ and Ppara-/- mice 
 
Plasma FFA, TG, and glucose were measured in 3-4 month old male Ppara+/+ (n=9) and Ppara-/- 
(n=5) mice that were fed or fasted for 16 hours. * indicates p < 0.05, data were compared by 




Figure 7 - Lipid measurements from hearts of fed and fasted Ppara+/+ and Ppara-/- mice 
 
Total lipids were extracted from hearts, and TG and FFA were measured. Lipid content was 













Fed and fasted Ppara+/+ and Ppara-/- mice heart sections (n=5) were stained with Oil Red O, 










Figure 9 - PAS staining of hearts from fed and fasted Ppara+/+ and Ppara-/- mice 
 
Fed and fasted Ppara+/+ and Ppara-/- mice heart sections (n=5) were stained with PAS reagent, 









Figure 10 - Glycogen content of hearts from fed and fasted Ppara+/+ and Ppara-/- mice 
 
Total glycogen was extracted from hearts of fed and fasted Ppara+/+ and Ppara-/- mice and 
digested with amyloglucosidase, and free glucose was measured. Glucose content was 




We then assessed heart glycogen storage in Ppara-/- mice to determine if these hearts 
depleted their stored carbohydrate. There was no difference in PAS staining of glycogen (Figure 
9) or extracted glycogen content (Figure 10) after fasting. There tended to be increased glycogen 
in Ppara-/- hearts both before and after fasting. 
Changes in genes required for lipid and glucose metabolism were determined in hearts of 
fed and fasted mice. Adipose TG lipase (Atgl), the rate limiting enzyme for intracellular TG 
lipolysis (127), was decreased by 50% in both fed and fasted Ppara-/- mice compared to Ppara+/+ 
(Figure 11). Expression of carnitine palmitoyl transferase (Cpt)1b, the rate limiting enzyme for 
mitochondrial lipid oxidation, was minimal in both fed and fasted Ppara-/- hearts. Surprisingly, 
mRNA of acyl CoA oxidase (Acox)1, the first enzyme in the lipid oxidation pathway, was 
increased in fasted Ppara-/- hearts. However, decreased FA oxidation has been previously 
observed in these hearts (261,262). Therefore, absence of TG stores was not likely due to 
increased FA oxidation. As expected, mRNA expression of lipid droplet protein genes Plin2 and 
Plin5 were minimal in both fed and fasted Ppara-/- mice compared to Ppara+/+ mice (169).  
Fasting dramatically increased expression of pyruvate dehydrogenase kinase (Pdk) 4, the 
negative regulator of glucose oxidation, in hearts from Ppara+/+ mice. Fasted Ppara-/- mice also 
had increased Pdk4 mRNA levels compared to fed Ppara-/- but these levels were still reduced 
compared to the Ppara+/+ counterparts. Fasted Ppara-/- mice had increased glucose transporter 
(Glut)1, the insulin insensitive glucose transporter, mRNA expression compared to fasted 
Ppara+/+ hearts, but there was no difference in Glut4, the insulin sensitive glucose transporter, 
expression. Most remarkable was that fed and fasted Ppara-/- hearts had an ~80% reduction in 
lipid uptake genes Cd36 and Lpl. 
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Figure 11 - Gene expression in hearts from fed and fasted Ppara+/+ and Ppara-/- mice 
 
Gene expression of Atgl, Cpt1b, Acox1, Plin2, Plin5, Cd36, Lpl, Pdk4, Glut1, and Glut4 was 
assessed using quantitative real-time PCR. Gene expression is expressed relative to fed Ppara+/+ 
mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared to Ppara+/+ 




We assessed heart mRNA levels of several genes involved in both de novo lipogenesis 
and TG formation. Expression of acetyl-CoA carboxylase (Acc) 2, which is rate-limiting for de 
novo lipogenesis, was increased in the hearts of fed Ppara-/- mice (FIGURE). FA synthase 
(Fasn); the second rate-limiting enzyme for de novo lipogenesis; mRNA expression was 
increased in the hearts of both fed and fasted Ppara-/- mice. Dgat1, the rate limiting enzyme for 
TG synthesis, mRNA levels were decreased in hearts from both fed and fasted Ppara-/- mice. We 
also measured gene expression of FA transporters other than Cd36. Hearts from both fed and 
fasted Ppara-/- mice had decreased expression of Slc27a1 (Fatp1), but increased expression of 
FA binding protein-plasma membrane (Got2, or FABPpm). Finally, we measured TG lipase 
activity in hearts of fed and fasted Ppara+/+ and Ppara-/- mice. Both fed and fasted Ppara-/- mice 





Figure 12 - Supplemental gene expression in hearts from fed and fasted Ppara+/+ and Ppara-
/- mice 
 
Gene expression of Slc27a1, Fatp6, Fabp3, Got2, Acc2, Fasn, Scd1, Dgat1, Dgat2, and Abhd5 
was assessed using quantitative real-time PCR. Gene expression is expressed relative to fed 
Ppara+/+ mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared to 




Figure 13 - TG lipase activity in hearts from fed and fasted Ppara+/+ and Ppara-/- mice 
 
Heart tissue lysates from fed and fasted Ppara+/+ and Ppara-/- mice (n=5) were incubated with 
[3H]-labelled triolein micelles to assess TG lipase activity.  # indicates p < 0.05 compared to 




Fasted Cd36-/- mice do not store lipids in the heart  
Next, we determined whether CD36 deficiency would be sufficient to prevent heart TG 
accumulation during the fasted state. Fasting increased plasma FFA 3-fold in Cd36-/- mice 
(Figure 14). Plasma TG tended to be higher in fasted Cd36-/- mice compared to Cd36+/+ mice. 
Fasted Cd36-/- had a ~50% decrease in plasma glucose. There was no significant TG 
accumulation in Cd36-/- hearts (Figure 15). Heart FA content also did not increase in hearts from 
Cd36-/- mice. Glycogen content was similar in all hearts (Figure 16). Finally, Cd36-/- mouse 
hearts tended to have decreased expression of lipid metabolism genes (Atgl, Cpt1b, Acox1, Atgl, 
Plin2, Plin5) in the fed state, but fasted Cd36-/- mice hearts had similar gene expression to 
Cd36+/+ mice (Figure 19). LpL mRNA levels were comparable to control mice in both fasting 
and fed hearts. Glucose oxidation and uptake genes (Pdk4, Glut1, and Glut4) were comparable 
between genotypes and feeding conditions. Fed and fasted Cd36-/- mice had decreased expression 
of Dgat2 (Figure 20). Hearts of fasted Cd36-/- mice had increased expression of Slc27a1, and 
both fed and fasted hearts had decreased expression of FA binding protein 3 (Fabp3). There were 




Figure 14 - Plasma biochemistry of fed and fasted Cd36+/+ and Cd36-/- mice 
 
Plasma FFA, TG, and glucose were measured in 3-4 month old male Cd36+/+ (n=9) and Cd36-/- 
(n=9) mice that were fed or fasted for 16 hours. * indicates p < 0.05 compared within genotype, 





Figure 15 - Lipid measurements from hearts of fed and fasted Cd36+/+ and Cd36-/- mice 
 
 
Total lipids were extracted from hearts of Cd36+/+ and Cd36-/- mice, and TG and FFA were 
measured. Lipid content was normalized to protein content. *indicates p < 0.05, data were 





Figure 16 - ORO staining of hearts from fed and fasted Cd36+/+ and Cd36-/- mice 
 








Figure 17 - PAS staining of hearts from fed and fasted Cd36+/+ and Cd36-/- mice  
 










Figure 18 - Glycogen content of hearts from fed and fasted Cd36+/+ and Cd36-/- mice 
 
Total glycogen was extracted from hearts of fed and fasted Cd36+/+ and Cd36-/- mice and 
digested with amyloglucosidase, and free glucose was measured. Glucose content was 




Figure 19 - Gene expression in hearts from fed and fasted Cd36+/+ and Cd36-/- mice 
 
Gene expression of Atgl, Cpt1b, Acox1, Plin2, Plin5, Cd36, Lpl, Pdk4, Glut1, and Glut4 was 
assessed using quantitative real-time PCR. Gene expression is expressed relative to fed Cd36+/+ 
mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared to Cd36+/+ 




Figure 20 - Supplemental gene expression in hearts from fed and fasted Cd36+/+ and Cd36-/- 
mice 
 
Gene expression of Slc27a1, Fatp6, Fabp3, Got2, Acc2, Fasn, Scd1, Dgat1, Dgat2, and Abhd5 
was assessed using quantitative real-time PCR. Gene expression is expressed relative to fed 
Cd36+/+ mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared to 








Figure 21 - TG lipase activity in hearts from fed and fasted Cd36+/+ and Cd36-/- mice 
 




Fasted hLpL0 mice do not store lipids in the heart  
If circulating FFAs are the source of heart TG stores during fasting, we would expect that loss of 
lipoprotein TG hydrolysis in the heart would not affect lipid droplet accumulation during fasting. 
To test this, we fasted hLpL0 mice and compared them to LpLflox/flox littermates. After fasting 
hLpL0 mice had normal increases in plasma FFA concentration, an approximately 2-fold 
increase (Figure 22). hLpL0 mice tended to have slightly elevated TG in the fasted state, as has 
been reported (195). Plasma glucose fell 20% in both LpLflox/flox and hLpL0 mice. Surprisingly, 
hLpL0 mice did not accumulate cardiomyocyte TG during fasting (Figure 23, Figure 24). 





Figure 22 - Plasma biochemistry of fed and fasted LpLflox/flox and hLpL0 mice 
 
Plasma FFA, TG, and glucose were measured 3-4 month old male LpLflox/flox (n=5) and hLpL0 





Figure 23 - Lipid measurements from hearts of fed and fasted LpLflox/flox and hLpL0 mice 
 
Total lipids were extracted from hearts of LpLflox/flox and hLpL0 mice, and TG and FFA were 
measured. Lipid content was normalized to protein content. * indicates p < 0.05 compared within 
genotype, # indicates p < 0.05 compared to LpLflox/flox mice of same feeding status; data were 




Figure 24 - ORO staining of hearts from fed and fasted LpLflox/flox and hLpL0 mice 
 





Figure 25 - PAS staining of hearts from fed and fasted LpLflox/flox and hLpL0 mice 
 





Figure 26 - Glycogen content of hearts from fed and fasted LpLflox/flox and hLpL0 mice 
 
Total glycogen was extracted from hearts of fed and fasted LpLflox/flox and hLpL0 mice and 
digested with amyloglucosidase, and free glucose was measured. Glucose content was 







We predicted that changes in gene expression in the fasting hLpL0 hearts would explain the lack 
of TG stores. mRNA levels of Atgl, Cpt1b, and Acox1 were reduced in both fed and fasted 
hLpL0 mice hearts (Figure 27), consistent with the reduction in FA oxidation in these hearts 
(47). hLpL0 mice also had decreased expression of Plin2 and Plin5 compared to fasted 
LpLflox/flox mice. Although these hearts do not have reduced FFA uptake, Cd36 mRNA was 
reduced in both fed and fasted hLpL0 hearts. Pdk4 expression was reduced in both fed and fasted 
hLpL0 hearts compared to LpLflox/flox hearts. Although glucose uptake is increased in hLpL0 
hearts (47), fasted Glut1 mRNA levels were lower than controls and did not differ between fed 
and fasted hLpL0 mouse hearts. Glut4 was also reduced in both fed and fasted hLpL0 hearts.  
Hearts from both fed and fasted hLpL0 mice had decreased diacylglycerol acyltransferase 
(Dgat) 1 mRNA expression (Figure 28). Fasted hLpL0 mice had less Dgat2 mRNA expression 
compared to fasted LpLflox/flox mice. The rate-limiting enzyme for production of monounsaturated 
FAs, stearoyl-CoA desaturase (Scd) 1, mRNA levels were decreased in hearts of fasted hLpL0 
mice. Expression of Slc27a1 was increased in fasted floxed LpL mouse hearts, but not as much 
in fasted hLpL0 mouse hearts. FA transport protein 6 (Fatp6), Fabp3, and Got2 were all 
decreased in hearts of fasted hLpL0 mice compared to fasted floxed LpL mice. There were no 




Figure 27 - Gene expression in hearts from fed and fasted LpLflox/flox and hLpL0 mice 
 
Gene expression of Atgl, Cpt1b, Acox1, Plin2, Plin5, Cd36, Lpl, Pdk4, Glut1, and Glut4 was 
assessed using quantitative real-time PCR. Gene expression is expressed relative to fed 
LpLflox/flox mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared 




Figure 28 - Supplemental gene expression in hearts from fed and fasted LpLflox/flox and 
hLpL0 mice 
 
Gene expression of Slc27a1, Fatp6, Fabp3, Got2, Acc2, Fasn, Scd1, Dgat1, Dgat2, and Abhd5 
was assessed using quantitative real-time PCR. Gene expression is expressed relative to fed 
LpLflox/flox mice. * indicates p < 0.05 compared within genotype, # indicates p < 0.05 compared 




Figure 29 - TG lipase activity in hearts from fed and fasted LpLflox/flox and hLpL0 mice 
 





Plin2 and Plin5 protein expression is not affected by cardiac lipid stores  
A reduction in PLIN2 prevents lipid accumulation in the liver (128,130) and we had noticed a 
reduction in Plin2 mRNA. For this reason we measured PLIN2 protein in the hearts of fed and 
fasted mice. Fasting increased PLIN2 protein in Cd36+/+ mice, and unexpectedly also in Cd36-/- 
mouse hearts (Figure 30). Band density measurement indicated about a 40-50% increase in 
PLIN2 after fasting in both Cd36+/+ and Cd36-/- mice (Figure 31). Because PLIN5 blocks TG 
lipolysis (136-138), a lack of change in mRNA but reduced protein could allow more rapid 
degradation of stored TG. Therefore, we measured Plin5 protein in the fed and fasted state. 
PLIN5 protein levels were highly variable (Figure 30), but not significantly different between the 
fed and fasted states (Figure 31). Similar changes in both PLIN2 and PLIN5 protein were 




Figure 30 - Western blot of PLIN2 and PLIN5 in hearts of fed and fasted Cd36+/+ and  
Cd36-/- mice 
 








Figure 31 - Band density analysis of PLIN2 and PLIN5 western blots in hearts of fed and 
fasted Cd36+/+ and Cd36-/- mice 
 
PLIN2 and PLIN5 protein content in hearts of Cd36+/+ and Cd36-/- mice. Protein was quantified 
by band density measurements of the western blot. Band densities were normalized to β-actin 
content within each sample. Data are expressed as relative amount compared to fed Cd36+/+ 











Figure 32 - Western blot of PLIN2 and PLIN5 in hearts of fed and fasted LpLflox/flox and 
hLpL0 mice 
 








Figure 33 - Band density analysis of PLIN2 and PLIN5 western blots in hearts of fed and 
fasted LpLflox/flox and hLpL0 mice 
 
PLIN2 and PLIN5 protein content in hearts of LpLflox/flox and hLpL0 mice was quantified by 
band density measurements of the western blot. Data were normalized to β-actin content within 
each sample and expressed as relative amount compared to fed LpLflox/flox mice. * indicates p < 




Blocking circulating TG degradation prevents cardiac lipid accumulation  
Because of the surprising observation that hLpL0 mouse hearts did not accumulate TG during 
fasting - a result suggesting that circulating TG are the primary substrate for cardiac lipid 
accumulation - we used a drug that blocks lipolysis of circulating TG. Mice were administered 
P407 and then fasted for 16 hours. Plasma TG increased 10-fold in the P407 treated mice, 
indicating a complete block of TG uptake (Figure 34). Surprisingly, plasma FFA and glucose 
concentrations were also higher in the P407 treated mice. Next, we looked at the heart lipids. As 
we found in the hLpL0 hearts, cardiac FFA were not affected by P407 treatment, but P407-
treated mice had 60% less TG than PBS treated mice (Figure 35). There was decreased Oil Red 





Figure 34 - Plasma biochemistry of fasted PBS and P407-treated mice 
 
Plasma FFA, TG, and glucose in 3-4 month old C57/BL6 male mice (n=5) that were injected 
intraperitoneally with 1 mg/g P407 or an equivalent volume of PBS. * indicates p < 0.05, data 




Figure 35 - Lipid measurements from hearts of fasted PBS and P407-treated mice 
 
 
Total lipids were extracted from hearts of fasted PBS and P407 treated mice (n=5), and TG and 
FFA were measured. Lipid content was normalized to heart weight. * indicates p < 0.05, data 





Figure 36 - ORO staining of hearts from fasted PBS and P407-treated mice 
 







We then measured uptake of circulating FFA in control and P407-treated mice. Plasma turnover 
of the label was identical in the control and treated mice (Figure 37). Heart uptake of the FFA 
was greater in the lipolysis-inhibited mice (Figure 38), consistent with a greater reliance of the 
heart on FFA than TG. Liver uptake of the label did not differ between groups. Next, we 
measured uptake of circulating glucose in control and P407-treated mice. Plasma turnover of the 
labeled glucose in plasma was the same in both groups of mice (Figure 39). Uptake of plasma 
glucose tended to be increased in P407-treated mice hearts (p=0.08) and livers (Figure 40). Total 





Figure 37 - Plasma disappearance of [3H]-oleate in fasted PBS and P407-treated mice 
 
Plasma disappearance of the [3H]-oleate was measured at 30 seconds, 1 minute, 3 minutes, and 5 




Figure 38 - Heart and liver uptake of FFA in fasted PBS and P407-treated mice 
 
Cardiac and hepatic FFA uptake were assessed using [3H]-oleate (n=4-5). * indicates p < 0.05, 




Figure 39 - Plasma disappearance of [14C]-2-deoxyglucose in fasted PBS and P407-treated 
mice 
 
Plasma disappearance of the [14C]-2-deoxyglucose was measured at 2 minutes, 30 minutes, and 




Figure 40 - Heart and liver uptake of glucose in fasted PBS and P407-treated mice 
 




Figure 41 - Glycogen content of hearts from fasted PBS and P407-treated mice 
 
Total glycogen was extracted from hearts of fasted PBS and P407-treated mice and digested with 
amyloglucosidase, and free glucose was measured. Glucose content was normalized to tissue 
weight. (n=4-5). 
Figure 42 - PAS staining of hearts from fasted PBS and P407-treated mice 
 
Fasted PBS and P407-treated mice heart sections (n=5) were stained with PAS reagent, 




Lipid metabolism genes tended to be increased with P407 but not all increases reached statistical 
significance. Cpt1b, Acox1, and Lpl were increased in P407-treated mice while increases in Atgl, 
Plin2, Plin5, and Cd36 were less robust (Figure 43). Pdk4 expression was not affected by P407-
treatment, but Glut1 and Glut4 were both increased in hearts of P407-treated mice. P407 treated 
fasted mice had increased heart expression of Fabp3 and tended to have increased expression of 
Fatp6 (Figure 44). There was a 30% increase in TG lipase activity in fasted mice treated with 




Figure 43 - Gene expression in hearts from fasted PBS and P407-treated mice 
Gene expression of Atgl, Cpt1b, Acox1, Plin2, Plin5, Cd36, Lpl, Pdk4, Glut1, and Glut4 was 





Figure 44 - Supplemental gene expression in hearts from fasted PBS and P407-treated mice 
 
Gene expression of Slc27a1, Fatp6, Fabp3, Got2, Acc2, Fasn, Scd1, Dgat1, Dgat2, and Abhd5 
was assessed using quantitative real-time PCR (n=4-5). * indicates p < 0.05, data were compared 





Figure 45 - TG lipase activity in hearts from fasted PBS and P407-treated mice 
 
Heart TG lipase activity was measured in fasted mice treated with either PBS or P407 (n=4-5). * 




Cardiac TG accumulation during fasting does not impair heart function  
Cardiac TG accumulation has been postulated to cause toxicity and to reduce heart function 
(182,263). To determine if TG accumulation during fasting affects cardiac function, we fasted 
mice overnight and measured FS before and after administration of isoproterenol. We used 
young mice – 3-4 months – prior to the development of severe heart dysfunction that occurs in 
the hLpL0 mice (47). Basal FS was similar (~40%) in fasted Cd36+/+ and Cd36-/- mice. 
Isoproterenol injection resulted in a maximum FS of 70% in fasted Cd36+/+ hearts and 60% in 
Cd36-/- hearts (Figure 45, Figure 46). Basal FS tended to be greater in LpLflox/flox mice (56%) 
compared to hLpL0 mice (47%), but LpLflox/flox and hLpL0 mice had a similar maximal increase 




Figure 46 - Basal and isoproterenol-stimulated fractional shortening in fasted Cd36+/+ and 
Cd36-/- mice 
 
3-4 month old male Cd36+/+ (n=10) and Cd36-/- (n=9) mice were fasted for 16 hours and then 
injected intraperitoneally with 1.5 mg/kg isoproterenol. Cardiac function was assessed with M-
mode echocardiography and fractional shortening was measured before and after injection of 




Figure 47 - M-mode images of basal and isoproterenol-stimulated fractional shortening in 
fasted Cd36+/+ and Cd36-/- mice 
 




Figure 48 - Basal and isoproterenol-stimulated fractional shortening in fasted LpLflox/flox 
and hLpL0 mice 
 
3-4 month old male LpLflox/flox (n=7) and hLpL0 (n=8) mice were fasted for 16 hours and then 
injected intraperitoneally with 0.3 mg/kg isoproterenol. Cardiac function was assessed with M-
mode echocardiography and fractional shortening was measured before and after injection of 




Figure 49 - M-mode images of basal and isoproterenol-stimulated fractional shortening in 
fasted LpLflox/flox and hLpL0 mice 
 





In this series of experiments, we studied the source of FAs required for heart lipid droplet 
formation. We first found that hearts from Ppara-/- mice did not accumulate lipid droplets, 
despite their increase in plasma FFA and reduced FA oxidation. FFA uptake into the heart may 
be mediated by several transporters and non-receptor-mediated movement of FFA across the 
membrane (254,255). The FA transporter CD36 facilitates a major fraction of the albumin-bound 
FFA uptake into cardiac cells (264) and also FFA derived from LpL hydrolysis of VLDL (30). 
Loss of either CD36 or LpL reduced lipid droplet stores. Since CD36 is downstream of LpL (30), 
we then used a chemical inhibitor of lipolysis to confirm that defective lipolysis in the presence 
of continued FFA uptake could prevent heart TG accumulation. In agreement with our 
conclusion, albumin-bound FFA were shown to be more likely to be oxidized and chylomicron 
TG-derived FFA more likely to be esterified (265). Our data contrast with studies in isolated 
hearts, in which supply of excess FFAs can drive lipid droplet formation (266,267). However, in 
vivo the majority of circulating FAs are esterified as TG and phospholipid (85-90%). Thus it 
would not be surprising that they also are a major supplier of heart FFA for TG storage. Finally, 
we showed that TG accumulation during overnight fasting did not impair or improve stimulated 
cardiac function. 
The PPAR family of transcription factors control lipid uptake, oxidation, and storage. 
The family members - PPARα, PPARβ/δ, and PPARγ - have overlapping transcriptional control 
of lipid metabolism gene expression. Two mouse models of heart specific PPAR overexpression, 
the MHC-PPARα and MHC-PPARγ transgenic mice, have increased lipid uptake, , increased 
neutral lipid storage, and increased lipid oxidation associated with cardiac dysfunction (202,247). 
Although Ppara-/- mice have increased fasting concentrations of plasma FFA (268), the 
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accumulation of heart lipids during fasting had not been assessed. We hypothesized that Ppara-/- 
mice, which have reduced FA oxidation in the heart (166), would accumulate more lipids during 
a prolonged fast. We found just the opposite; TG accumulation was drastically reduced. Was this 
due to a defect in lipid droplet production, greater lipolysis of the stored TG, or reduced lipid 
uptake into these hearts? Since lipid uptake is upstream of lipid storage and turnover, it seems 
most likely that a deficiency of lipid uptake would precede any intracellular metabolic 
abnormalities. 
Several mouse models do not accumulate cardiac lipids during fasting. Mice deficient in 
HSL, an intracellular TG and diacylglycerol lipase, do not accumulate cardiac lipids during 
fasting, presumably due to the reduced ability of the adipose tissue to lipolyze stored TG and 
release FFA (226). HSL knockout mice have lower fasting plasma FFA and TG concentrations 
and decreased heart FFA uptake (226). Conversely, cardiomyocyte-specific HSL overexpressing 
mice also do not accumulate lipids after prolonged fasting because of rapid lipid droplet turnover 
(207). Ppara-/- mice did not have an increase in ATGL expression; in fact, mRNA levels of 
ATGL were dramatically reduced. 
Another modulator of intracellular TG lipolysis is the lipid droplet protein PLIN5. 
Recently, Plin5-/- mice were described to have defective storage of lipids in the heart (136); 
PLIN5 is responsible for regulating ATGL activity, thus with PLIN5 deficiency intracellular 
lipase activity is constantly turned on. Plin4 deletion resulted in a similar phenotype due to a 
consequent decrease in Plin5 expression (133). Overexpression of PLIN5 increased heart TG 
content (137,138). Plin2-/- mice had decreased lipid accumulation in the liver and may play a 
similar role in promoting lipid accumulation (128). As others have reported (169), we observed 
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that Plin2 and Plin5 mRNA were dramatically reduced in Ppara-/- mice hearts; these genes are 
canonical PPARα target genes. Therefore, defects in lipid droplet formation in Ppara-/- mice 
could be due to lack of PLIN2 or PLIN5 or, more likely, the reductions in PLIN2 and PLIN5 are 
secondary to reduced PPARα activation. Surprisingly, intracellular TG lipase activities were 
dramatically increased in Ppara-/- mice – perhaps due to decreased Plin2 and Plin5 expression. 
Others have demonstrated a fasting-induced increase of TG lipase activity in the heart of wild-
type animals (143); we did not find this to be the case. 
mRNA levels for Cd36 and Lpl were both markedly reduced in the Ppara-/- mice. 
Therefore, we fasted mice that were deficient in CD36 or heart LpL. Cd36-/- mice have decreased 
cardiac FFA uptake and decreased VLDL-TG uptake, whereas hLpL0 mice have normal to 
increased cardiac FFA uptake and decreased VLDL-TG uptake (30,80). Since the concentration 
of circulating FFA increases during fasting, and mice that do not mobilize adipose lipid stores 
during fasting do not accumulate cardiac lipids (226), we hypothesized that FFA are the primary 
substrate for lipid accumulation in the hearts of fasted mice. We expected that Cd36-/- mice 
would not form lipid droplets after an overnight fast, but hLpL0 mice would form lipid droplets. 
As expected, fasted Cd36-/- mice failed to accumulate lipids in the heart. Surprisingly, the hLpL0 
mice also failed to accumulate cardiac lipids. 
We still believed that FFA were driving this process, so we hypothesized that the lipid 
droplet was not stabilized and was turned over more rapidly in hLpL0 mice. hLpL0 mice have 
decreased PPARα target gene expression (195,217), so we suspected that lipid droplet proteins 
PLIN2 and PLIN5 were also reduced. We found that Plin2 mRNA levels were reduced in both 
the fed and fasted state. However, Plin5 mRNA was normal. As there is often a mismatch 
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between Plin2 and Plin5 message and protein content, we assayed protein with Western blotting. 
Protein expression in the heart were comparable for each genotype, and fasting increased heart 
PLIN2 modestly in all genotypes. PLIN5 was comparable between control and hLpL0 mice with 
both feeding conditions. Finally, we measured heart intracellular TG lipase activity and there 
was no difference between LpLflox/flox mice and hLpL0 mice. Thus, we concluded that despite 
decreased PPARα target gene expression, it was unlikely that a defect in storage was preventing 
lipid accumulation in hLpL0 mice.  
We then posited that VLDL-TG, and not FFA, were the source of the cardiac lipid for 
droplet accumulation observed in fasting. Indeed, cardiac LpL activity is increased after an 
overnight fast, suggesting an important role for circulating TG in supplying the heart with lipids 
(269,270). To test this hypothesis, we treated mice with P407, a detergent that interferes with 
lipolysis of circulating lipoproteins. P407 treatment dramatically reduced cardiac lipid 
accumulation, but did not reduce PPARα target gene expression. Furthermore, P407-treated mice 
had increased FFA uptake, yet still failed to form lipid droplets. However, the decrease in lipid 
droplet formation could be the result increased intracellular TG lipase activity; it is unclear why 
intracellular TG lipase activity was increased in the P407 treated mice. We observed that P407 
treatment and fasting together dramatically increased plasma FFA; plasma FFA concentrations in 
P407 treated mice were 5-fold greater than those in plasma of non-treated fasting mice. This 
increase may be partially due to the partitioning of plasma FFA onto VLDL particles (Figure 50). 
We concluded that TG, and not FFA, are the primary substrate for cardiac lipid accumulation 




Figure 50 - Distribution of plasma FFA in lipoprotein fractions 
 
Plasma from PBS and P407-treated 16-hour fasted mice (n=4-5) was fractionated with density 
ultracentrifugation. 1.006 g/mL corresponds to the VLDL fraction; 1.12 g/mL corresponds to the 
LDL fraction; 1.34 g/mL corresponds to the HDL fractions; >1.34 g/mL refers to the 
albumin/FFA fraction. Counts of [3H]-oleate were measured in each lipoprotein fraction and 
reported as percentage of total counts in plasma. * indicates p < 0.05. Data were compared by 
Student’s t-test.  
 




In these studies, we focused on lipid uptake pathways that modulate TG accumulation in 
the hearts of fasted animals. As the heart is a dynamic organ that possesses the ability to use 
multiple substrates, we asked whether hearts in fasted animals that have defective lipid uptake 
might have changes in glucose utilization. Mice that have decreased lipid uptake in 
cardiomyocytes tend to increase glucose uptake and catabolism (47,271). We suspected that this 
might be happening in mice that failed to store lipid droplets in the cardiomyocytes. Heart gene 
expression of Pdk4, a negative regulator of glucose oxidation, was increased in all fasted mice, 
but to a lesser degree in mice that had deficiencies in lipid uptake. This likely indicates an 
increased reliance on glucose oxidation, i.e. pyruvate conversion to acetyl-CoA. Although gene 
expression of the glucose transporters GLUT1 and GLUT4 was variable, it has been previously 
demonstrated that Ppara-/- mice (214), Cd36-/- mice (57), and hLpL0 mice (47) all have increased 
cardiac glucose uptake. P407-treated fasting mice, which did not accumulate TG in 
cardiomyocytes, tended to have increased glucose uptake. However, glycogen content of hearts 
was similar for all genotypes, regardless of feeding status. We should note that others have 
reported increased heart glycogen with fasting (272). 
We would have liked to assess where the albumin-bound FFA from adipose lipolysis and 
the FFA from LpL’s action on circulating TG were going once they entered the cardiomyocyte. 
Different pools of circulating lipids, either FFA or TG, may enter the cardiomyocyte and be 
immediately oxidized, or they may be esterified as TG and later oxidized, or some combination 
of the two. FA turnover in the heart is very rapid with hydrolysis of much the pool of FAs within 
10 minutes (47). Thus, assessing the residual FAs from labeled FFA or VLDL-TG is 
challenging. There are a number of elegant studies that have used isolated perfused hearts to 
track uptake, oxidation, and esterification of labeled TG in chylomicrons and VLDL 
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(185,263,273,274). However, methods to study tracer uptake and oxidation in vivo and not in 
perfused hearts are not available.  It is likely that LpL-mediated accumulation of heart TG during 
fasting is reflective of the much greater amount of circulating lipids that reside in TG particles. 
The total amount of albumin-bound FFA might be insufficient to alone promote heart lipid 
accumulation during fasting. In support of the importance of TG as a source of heart lipids, 
lipotoxic mice that have excessive cardiac lipid accumulation are cured with cardiac-specific 
LpL knockout (217). Furthermore, it might also be that FAs from different sources diverge in 
their intracellular fate. In support of this, one study of isolated perfused hearts found that FFAs 
were primarily oxidized, while FAs from chylomicrons divided equally into oxidation and 
cellular storage (265). 
We assessed intracellular TG lipase activity to determine whether increased turnover of 
lipid droplets might explain why we did not see fasting-induced cardiac lipid accumulation in 
Ppara-/- mice, Cd36-/-, hLpL0, and P407-treated mice. Surprisingly, we found there was 
dramatically increased TG lipase activity in Ppara-/- mice, despite the reduction in Atgl mRNA. 
The deficiency of Plin2 and Plin5 that others and we have observed (169) in these mice could 
also indicate greater TG turnover. We also observed an increase in heart TG lipase activity in 
fasted mice treated with P407. However, there were no differences in heart TG lipase activity 
between Cd36-/- or hLpL0 mice and wild-type or floxed controls. 
Although our data and others implicate LpL and CD36 as the primary players in cardiac 
lipid accumulation, it is possible that mice deficient in these proteins will have a reduction in 
other lipid transporters or de novo lipogenesis. We assessed mRNA expression of a number of 
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other genes and found that some of these genes had increased expression, but this was not 
sufficient to restore TG lipid droplet accumulation. 
Lipid droplet accumulation is thought to occur due to an imbalance between lipid uptake 
and oxidation. This involves PPARα driven expression of LpL and CD36, allowing increased 
uptake of circulating lipoprotein TG (Figure 51). Whether TG accumulation is toxic is 
unresolved (229). Lipid droplets are found in hearts of patients with diabetes and metabolic 
syndrome (197-199) and in hearts of high fat diet-fed rodents and genetically altered mice (182). 
Lipotoxicity can occur when ceramides, diacylglycerol, or other lipid species can alter cardiac 
cell signaling, disrupt membrane function, or cause apoptosis (275). We measured ceramides in 
hearts of fasted wild-type mice and did not observe an increase in ceramides coinciding with 
increased TG content (Figure 52). Excessive FFA oxidation has been proposed to lead to 
mitochondrial dysfunction, apoptosis and heart failure (190). For this reason, we tested whether 
increased stored lipid would reduce stimulated heart function. It did not. We found that short-




Figure 51 - Pathways of Lipid Uptake Leading to Lipid Droplet Formation 
 
PPARα drives lipid accumulation by regulating transcription of lipid uptake proteins LpL and 
CD36. Although both LpL and CD36 are required for cardiac lipid accumulation, LpL mediated 




Figure 52 - Ceramide measurement in fed and fasted wild-type mice 
 
Individual ceramide species and total ceramides were measured from hearts of fed and 16-hour 
fasted wild-type mice (n=9). * indicates p < 0.05 compared to fed mice. Data were compared by 





Although several models of lipid-induced heart dysfunction have massively increased 
amounts of heart TG, others have increases similar to that we found with fasting. ATGL 
knockout mice have 20 times the amount of cardiac lipids at 12 weeks of age and dramatically 
decreased heart function leading to 50% mortality by 18 weeks of age(127).  However, two 
groups recently reported that PLIN5 overexpression and a 3-10-fold increase in cardiac TG led to 
only mild heart dysfunction (137,138). Less dramatic increases in TG are occasionally associated 
with heart dysfunction, however, in those hearts DAGs and ceramides also are increased (244). 
We have previously reported a model of 50% increased cardiac TG in the fed state that is not 
associated with decreased cardiac function – the MHC-DGAT1 mouse model (229). In fact, this 
transgene reduces toxicity in other models without changing TG concentrations, but reducing 
heart ceramide 20% (229). In another model,  transgenic MHC-PPARγ mice, a similar 2-3 fold 
increase in myocardial TG but coupled to increased DAG and ceramide  was associated with 
more than a 50% reduction in FS (200,202,276). The effects of diets and diabetes on heart TG 
and other lipids and cardiac function are less clear. Three weeks of high fat diet feeding 
increased heart TG by 2-3 fold, but a 20% decrease of FS was only observed after 20 weeks high 
fat diet feeding (230,277). Streptozotocin-diabetic mice had a 50% increase in cardiac TG after 
12 weeks associated with a 20% reduction of FS (278). Ob/ob and db/db mice all have varying 
degrees of increased cardiac TGs (from 2-fold to 4-fold) associated with heart dysfunction 
depending on the duration of the study (248,279). Concentrations of ceramides and DAGs were 
often not measured in these models.  Increased heart TG content is sometimes, but not always, a 
hallmark of increased accumulation of others lipids, many of which are harmful to the heart.  
Storage of TGs in the heart may be an adaptive response to decreased energy intake 
during starvation. However, it also occurs in the setting of pathological conditions including 
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obesity, diabetes, and non-ischemic heart failure (280,281). Moreover, one report has suggested 
that heart lipid droplet accumulation occurs post-ischemia and is associated with more tissue 
damage (45). As we note above, lipid droplet accumulation is sometimes associated with heart 
dysfunction and also increased concentrations of potentially toxic lipids such as ceramides and 
DAGs, but in other situations TG storage alone does not lead to heart dysfunction (182). 
Whether the association between heart TG and function in humans is due to TG or other 
accumulated lipids is not obvious. It should be noted that severe heart failure in humans leads to 
reduced heart TG, but an increase in potentially toxic ceramides and DAGs (282). Our data show 
that lipid droplets, at least those that occur during fasting, do not affect heart function. 
In summary, our studies show that LpL-lipolysis of TG is required to store lipid in the 
heart of a fasting mouse. This study further confirms previous work showing that hearts are 
active organs in TG metabolism. We now show that the very high level of cardiac LpL 





Chapter 4: Conclusions and future directions 
These studies are a small contribution to the tremendous body of work that demonstrates 
the critical role of lipid metabolism for both the normal function of the heart and in the setting of 
cardiac dysfunction. In particular, they highlight the importance of the uptake of circulating TG 
for cardiac metabolism during starvation (Table 5). Several, but not all, mouse models of 
impaired cardiac lipid uptake develop cardiac dysfunction (47,98,99,239). However, prevention 
of excess lipid uptake and oxidation has been demonstrated to have beneficial effects in a 
number of in vitro studies (190). Since this work suggests that uptake of circulating TG may be 
more important for driving lipid accumulation, this implies that decreasing TG uptake may be 
beneficial in some settings of cardiac dysfunction. Indeed, previous work has shown that Vldlr-/- 
mice have decreased TG accumulation after myocardial infarction as well as improvements in 
markers of cardiac function (45). 
In order to transition these findings into a clinically relevant model, future studies will 
assess the effects of the inhibition of cardiac TG accumulation after myocardial infarction. The 
animal models described – Cd36-/- mice, hLpL0 mice, and P407-treated mice - will be used to 
evaluate changes in heart function and toxic lipid accumulation in both acute and chronic models 
of myocardial infarction. In brief, animals would be surgically infarcted in the left anterior 
descending artery and allowed to recover; heart function would be evaluated by measuring 
fractional shortening. Mice that have reduced cardiac TG accumulation could be protected from 
development of heart dysfunction. Indeed, excessive FFA uptake and oxidation has been linked 
to dysfunction in several acute injury models (283). It is likely that the Cd36-/- mice, which have 
defects in both FFA and TG uptake, may have improved heart function after infarction. Mice that 
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only have a defect in TG uptake – the hLpL0 mice and P407 treated mice – still avidly obtain 
circulating FFA. This would point specifically to a role for circulating FFA, and not TG, in 
promoting cardiac lipotoxicity in acute settings. Moreover, a number of in vitro studies using 
isolated perfused hearts suggest that FFA are acutely toxic (263,283). 
To the same end, these findings will be used to ameliorate cardiac lipotoxicity in a model 
of diet-induced obesity. The knockout mice – Cd36-/- and hLpL0 mice - would be made obese by 
8-12 weeks of high-fat diet feeding, which has been shown to induce cardiac dysfunction (230). 
Both mouse models should have improved cardiac function associated with reduced cardiac lipid 
accumulation. Indeed, deletion of either Cd36 or Lpl has been demonstrated to ameliorate 
cardiac lipotoxicity in a transgenic model (217,238). Similar studies may be conducted to assess 
whether inhibition of TG accumulation may also improve cardiac function in streptozotocin-
diabetic mice. 
Of most interest to these studies is developing a potential human therapy – for both the 
infarcted heart and for cardiac dysfunction associated with obesity. The most promising option is 
to inhibit VLDL-TG secretion via the use of ApoB or MTTP inhibitors, which reduce circulating 
TG concentration (284,285). This is an attractive option as an ApoB antisense drug, mipomersen, 
is currently undergoing clinical trials (285). Since either ApoB or MTTP inhibition almost 
completely ablates VLDL-TG secretion, there should be no cardiac lipid accumulation in fasting 
mice. The next step is to pre-treat mice before surgical infarction to determine whether cardiac 
lipotoxicity is ameliorated and whether there are any changes in heart function. Finally, the drug 
will be administered in a rodent model of chronic infarction to determine whether reduction of 
TG might ameliorate the deterioration of heart failure. 
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Finally, future developments in nuclear imaging and magnetic resonance spectroscopy 
should elucidate the differential fates of FFA that come from albumin-FFA versus LpL-lipolysis 
of circulating TG in vivo. These studies may prove useful in preventing excessive lipid 
accumulation associated with decreased cardiac function. Current state of the art imaging and 
spectroscopy is better developed in skeletal muscle or liver than in heart (286-288). Future 
developments may allow the investigation of the intracellular fates of circulating FFA versus TG, 
as well as carbohydrate and amino acid metabolites. 
Finally, it is unclear why the P407-treatment increased circulating glucose and FFA 
concentrations. It is likely that inhibiting LpL-hydrolysis of circulating TG triggers a stress 
response; this plasma concentration of stress hormones epinephrine, norepinephrine, and 
glucagon will be measured. These hormones stimulate increases in plasma FFA and glucose 
concentrations. This raises the interesting question of how the adrenal glands and pancreas sense 
energy balance, and suggests that LpL is critical for the regulation of stress hormone levels. 
Tissue specific knockouts of LpL in the adrenal glands and pancreatic α-cells (which secrete 
glucagon) may result in increased catecholamines and glucagon. This would directly link plasma 
TG concentration to the regulation of gluconeogenesis and WAT lipolysis and provide novel 
insight into the dysregulations in metabolic disease. 
In conclusion, this thesis suggests future studies and potential clinical interventions 
targeting cardiac lipid metabolism that may play a critical role in the treatment of heart 
dysfunction. Addressing these additional questions will provide further insight into the specific 
role of circulating metabolites in cardiac physiology and pathology.  
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Table 5 - Models of altered cardiac TG accumulation during starvation 
Model Reference Heart TG Explanation 
MHC-HSL (207) Decreased Increased IMTG lipolysis 
Hsl-/- (226) Decreased Very low FFA/TG in circulation 
Plin4-/- (133) Decreased Decreased Plin5 expression 
Plin5-/- (136) Decreased Removal of lipolytic barrier 
MHC-ATGL (289) Decreased Increased IMTG lipolysis 
MHC-Plin5 (138) Increased Decreased ATGL activity 
MHC-Plin5 (137) Increased Lipid droplet protected from ATGL 
Ppara-/- (250) Decreased Decreased expression of Cd36, LpL; possibly 
decreased expression of Plin2, Plin5 
Cd36-/- (250) Decreased Decreased LpL activity 
hLpL0 (250) Decreased Decreased LpL activity 
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